[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 352
1. Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA: Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg; 2010 Jan;139(1):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas.
  • OBJECTIVE: Distal esophageal tumors and gastric cardia tumors, although only physically separated by centimeters, have different staging systems and are usually treated differently.
  • We hypothesized that gastroesophageal junction adenocarcinomas (eg, gastric cardia and distal esophageal tumors) were not distinct entities and had similar survival.
  • METHODS: Using the Surveillance, Epidemiology, and End Results database (1988-2005), we identified patients with adenocarcinomas of the distal esophagus (n = 1474) and gastric cardia (n = 192).
  • RESULTS: Even after adjusting for potential confounding covariates (location, stage, race, cancer-directed surgery, and radiation therapy), we found no significant difference between distal esophageal and gastric cardia tumors with regard to overall (hazard ratio, 1.18; 95% confidence interval, 0.99-1.41) and cancer-specific (hazard ratio, 1.09; 95% confidence interval, 0.90-1.31) survival.
  • CONCLUSION: Through a large, population-based analysis of gastric cardia and distal esophageal adenocarcinomas, we found that patients with gastroesophageal junction adenocarcinomas have similar survival rates.
  • Adenocarcinomas of the gastroesophageal junction are not distinct entities delineated by anatomic boundaries and as such should be managed by one skilled in both esophageal and gastric resections.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 19660401.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Ki Kang W, Kim M, Kim S, Park CK, Kim S: Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology; 2010 Jul;139(1):84-92.e2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma.
  • BACKGROUND & AIMS: Lymphoepithelioma-like carcinoma (LELC) is a rare subtype of gastric carcinoma (GC) with a better survival rate than other GCs; most cases of LELC are associated with Epstein-Barr virus (EBV) infection.
  • EBV-associated GCs were subclassified, based on the pattern of host inflammatory immune responses, into 3 histologic subtypes: typical LELC (n = 53, 43.1%), Crohn's disease-like lymphocytic reaction (CLR) (n = 52, 42.3%), and conventional adenocarcinoma (n = 18, 14.6%).
  • RESULTS: Patients with EBV-associated GC had tumors of proximal location, lower N stage (P < .0001), and lower T stage (P = .02) and were older than controls (P = .0003).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20398662.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


3. Fujita T, Katai H, Morita S, Saka M, Fukagawa T, Sano T: Short-term outcomes of Roux-en-Y stapled anastomosis after distal gastrectomy for gastric adenocarcinoma. J Gastrointest Surg; 2010 Feb;14(2):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term outcomes of Roux-en-Y stapled anastomosis after distal gastrectomy for gastric adenocarcinoma.
  • METHODS: We evaluated the data of 701 consecutive patients of gastric adenocarcinoma who underwent conventional open distal gastrectomy with Roux-en-Y reconstruction.
  • The data collected included details on the method used for the Roux-en-Y reconstruction, the disease stage, extent of lymph node dissection, performance rate of truncal vagotomy, operation time, operative blood loss, length of hospital stay, and postoperative complications.
  • Postoperatively, delayed gastric emptying occurred in 14 (1.9%) patients, including seven (4.2%) from the MS group and seven (1.3%) from the HS group (p = 0.038).
  • CONCLUSION: There were no significant disadvantages of employing mechanical stapling for anastomosis, except for the high rate of delayed gastric emptying.
  • More consideration therefore needs to be given to decreasing the frequency of gastric emptying disturbance post surgery using mechanical staples.
  • [MeSH-major] Adenocarcinoma / surgery. Anastomosis, Roux-en-Y / methods. Gastric Bypass / methods. Stomach Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Emptying. Humans. Male. Middle Aged. Retrospective Studies. Suture Techniques. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1996 Jul;172(1):24-8 [8686797.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):900-4 [3664221.001]
  • [Cites] Int J Clin Oncol. 2007 Dec;12(6):433-9 [18071862.001]
  • [Cites] Am J Surg. 1981 Jan;141(1):143-7 [7006425.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):50-2 [2405935.001]
  • [Cites] Am J Surg. 1980 Jan;139(1):147-52 [6985775.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):305-9 [15783056.001]
  • [Cites] Arch Surg. 1975 Sep;110(9):1079-82 [1098615.001]
  • [Cites] Br J Surg. 1986 May;73(5):345-8 [3518855.001]
  • [Cites] Am J Surg. 1988 Mar;155(3):490-4 [3344916.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):337-41 [2021851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):456-60 [3510704.001]
  • [Cites] Adv Surg. 1994;27:233-55 [8140975.001]
  • [Cites] World J Surg. 2002 Dec;26(12):1452-7 [12370787.001]
  • [Cites] Ann Surg. 1984 May;199(5):590-7 [6721608.001]
  • [Cites] Gastric Cancer. 2004;7(1):24-30 [15052436.001]
  • [Cites] Surg Today. 2007;37(2):122-6 [17243030.001]
  • [Cites] Am J Surg. 1989 Mar;157(3):282-6 [2919731.001]
  • [Cites] Br J Surg. 1982 Dec;69(12):722-4 [6756537.001]
  • (PMID = 19904576.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Fatouros M, Roukos DH, Lorenz M, Arampatzis I, Hottentrott C, Encke A, Kappas AM: Impact of spleen preservation in patients with gastric cancer. Anticancer Res; 2005 Jul-Aug;25(4):3023-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of spleen preservation in patients with gastric cancer.
  • BACKGROUND: Resection of the spleen en bloc with the stomach for gastric cancer is still widely performed for a curative resection (R0), but the presence of the spleen may have a favorable effect on recurrence control and survival.
  • PATIENTS AND METHODS: Patients were included who underwent gastrectomy, with or without splenectomy, for gastric adenocarcinoma.
  • Since at baseline there was a significant imbalance of tumor stage in favor of the spleen-preservation group, we conducted a stage-stratified subgroup analysis.
  • CONCLUSION: Our findings indicate that preservation of the spleen may be associated with a reduced risk of early and overall recurrence translated into a better survival in patients receiving curative surgery for gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Spleen / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080561.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN: Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori; 2005 Nov-Dec;91(6):513-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
  • The authors investigated the correlation between clinicopathologic variables including survival and the overexpression of the p185(HER2) with loss of PTEN expression in gastric adenocarcinoma patients.
  • METHODS: The protein expression of p185(HER2) and PTEN was examined by immunohistochemical stain in paraffin-embedded tissues of 94 (M:F, 52:42) gastric adenocarcinoma patients by using monoclonal antibody, and the results were related to clinicopathological variables and survival.
  • Loss of PTEN expression correlated positively with depth of invasion (T stage) and was more frequent in the advanced stage.
  • CONCLUSIONS: Our observations suggest potential prognostic significance of p185(HER2) overexpression with PTEN loss in gastric adenocarcinoma patients.
  • This opens up the possibility of considering p185(HER2)and PTEN as a therapeutic target in gastric cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. PTEN Phosphohydrolase / analysis. Receptor, ErbB-2 / analysis. Stomach Neoplasms / chemistry. Stomach Neoplasms / pathology


6. Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA, Tsigris C, Rallis G, Vlasis K, Patsouris E: Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance. Virchows Arch; 2007 May;450(5):519-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance.
  • Nuclear factor (NF)-kappaB is a transcription factor constitutively activated in various neoplasms, including gastric carcinoma.
  • Furthermore, no data is available about the interaction of NF kappaB with its inhibitory protein I kappaB a in gastric carcinoma cases.
  • Nuclear NF kappaB 1/p50 was associated with stage (p = 0.0388), the depth of invasion (p = 0.0382), World Health Organization (WHO; p = 0.0326) and Lauren's histological classification (p = 0.0046).
  • Our results suggest that NF kappaB 1/p50 nuclear expression and therefore activation is regulated by its interaction with I kappaB a and that the former may serve as a useful independent molecular marker for stratifying patients with gastric carcinoma in terms of prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. I-kappa B Proteins / metabolism. NF-kappa B / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):119-27 [9918209.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7334-43 [16243805.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6845-52 [10602460.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1071-5 [15154625.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6938-47 [10602468.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4136-42 [11751513.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2567-77 [10353600.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Dec;3(6):793-8 [14686701.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):618-23 [16731602.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):14008-14 [9593751.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2518-25 [15814628.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10 (7):2466-72 [15073126.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):999-1003 [7675461.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):243-8 [16798222.001]
  • [Cites] Blood. 1999 May 1;93(9):3044-52 [10216101.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):491-500 [15024310.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1987-94 [9365245.001]
  • [Cites] Trends Mol Med. 2002 Aug;8(8):385-9 [12127724.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6867-74 [10602462.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3629-39 [9199297.001]
  • [Cites] Genomics. 1995 Sep 20;29(2):490-5 [8666399.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6134-43 [16273640.001]
  • [Cites] World J Gastroenterol. 2006 May 21;12(19):2979-90 [16718776.001]
  • [Cites] World J Gastroenterol. 2004 Jan 15;10(2):177-81 [14716817.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1029-37 [15297971.001]
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3846-9 [15991280.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6842-4 [10602459.001]
  • [Cites] Biochem Pharmacol. 1994 Jan 13;47(1):145-9 [8311838.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3197-203 [15929167.001]
  • [Cites] Biomarkers. 2006 Mar-Apr;11(2):184-93 [16766394.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):924-32 [15920558.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2274-81 [11147598.001]
  • [Cites] HNO. 1998 Jun;46(6):614-25 [9677498.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14 ):3032-9 [9230219.001]
  • [Cites] Virchows Arch. 2005 May;446(5):475-82 [15856292.001]
  • (PMID = 17429689.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / I-kappa B Proteins; 0 / NF-kappa B
  •  go-up   go-down


7. Macdonald JS: Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol; 2005 Jun 1;90(3):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of post-operative chemoradiation in resected gastric cancer.
  • The curative management of gastric adenocarcinoma depends upon complete resection of the primary tumor.
  • Intergroup study (INT-0116) demonstrated that combined chemoradiation following complete gastric resection improves median time to relapse (30 vs. 19 months, P < 0.0001) and overall survival (35 vs. 28 months, P = 0.01).
  • The recent publication of the first large adequately powered III neoadjuvant chemotherapy trial suggested this technique might down-stage tumors and increase resectability.
  • Future advances in the therapy of resectable gastric cancer may come from studies of pre-operative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and anti-angiogenesis agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • [CommentIn] J Surg Oncol. 2005 Jun 1;90(3):171-3; discussion 173 [15895446.001]
  • (PMID = 15895449.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 17
  •  go-up   go-down


8. Cui M, Yu W, Dong J, Chen J, Zhang X, Liu Y: Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Med Oncol; 2010 Sep;27(3):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma.
  • The expression of ABI1 and its role in cancer progression and prognosis are largely unknown in the majority of solid tumors, including gastric cancer.
  • In this study, we analyzed the correlation between ABI1 expression and the clinicopathological characteristics, tumor progression, and prognosis of patients with gastric carcinoma.
  • Tissue specimens were from 103 gastric cancer patients who underwent gastrectomy in our hospital between January 2000 and December 2007.
  • Meanwhile, quantitative real-time RT-PCR and Western blotting were used to identify the expression of ABI1 in human gastric normal mucosal cell line (GES-1) and gastric cancer cell lines (N87, AGS).
  • The immunohistochemical staining results of 59 patients showed that ABI1 was expressed in 28.8% (17/59) of gastric cancer tissues, compared to 91.5% (54/59) of normal samples.
  • ABI1 expression in 103 patients was strongly correlated with tumor differentiation, clinical stage, and lymph node status (P < 0.01).
  • Downregulation of ABI1 expression in human gastric carcinoma may play a critical role in tumor progression and in determining patient prognosis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Adenocarcinoma / genetics. Cytoskeletal Proteins / physiology. Neoplasm Proteins / physiology. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):7-10 [8033753.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1405-8 [12390382.001]
  • [Cites] Orv Hetil. 2005 Jun 12;146(24):1293-9 [16025998.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1669-77 [18347167.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1415-24 [9585502.001]
  • [Cites] FEBS Lett. 2003 Apr 10;540(1-3):195-200 [12681507.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):51-56 [11957043.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):345-54 [15180500.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1717-24 [18453543.001]
  • [Cites] BMC Cancer. 2008 Jan 28;8:25 [18226209.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5237-44 [15289329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1098-103 [15657136.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Oncologist. 2006 Feb;11(2):136-45 [16476834.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31290-7 [16899465.001]
  • [Cites] Exp Cell Res. 2005 Nov 1;310(2):463-73 [16182283.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2583-97 [7590237.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):1031-9 [17951403.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4926-34 [11526477.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):233-41 [9010225.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):4-10 [16343889.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28954-60 [11387320.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7591-601 [11003655.001]
  • [Cites] Neoplasia. 2001 Mar-Apr;3(2):99-104 [11420744.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):57-9 [12547160.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 19554484.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABI1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


9. Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS, Chung HC: Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol; 2008 Mar;19(3):520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
  • BACKGROUND: This phase III trial was to compare 5-fluorouracil (5-FU), adriamycin, and polyadenylic-polyuridylic acid (poly A:U) against 5-fluorouracil plus adriamycin (FA) for operable gastric cancer.
  • The survival benefits were prominent in the subset of patients with T3/T4a, N2, or stage III.
  • CONCLUSIONS: These results indicate a survival advantage of chemoimmunotherapy with a regimen of FA and poly A:U in curatively resected gastric adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029971.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 24936-38-7 / Poly A-U; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Di Martino N, Izzo G, Cosenza A, Vicenzo L, Monaco L, Torelli F, Basciotti A, Brillantino A, Marra A: [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?]. Suppl Tumori; 2005 May-Jun;4(3):S84-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?].
  • INTRODUCTION: Gastric cancer is the second tumor for frequency in the world.
  • Indeed lymphonodal metastasis seem to be one of the most important prognostic factors in the gastric cancer and the level and the number of metastatic nodes are useful to predict the patients' survival.
  • The aim of this study is to value the D2 lymphadenectomy in the patients who were treated with total gastrectomy for gastric adenocarcinoma, comparing the results both with the D1 lymphadenectomy and the D3-D4, paying attention to the survival rates related with the lymphonodal dissection.
  • PATIENTS AND METHOD: From 1998 to 2004, we studied 87 patients with gastric cancer.
  • We followed the Japanese Research Society for Gastric Cancer guidelines, according to which nodes are gathered into 16 levels and divided in 4 groups (N1-N4) depending on the cancer localization.
  • The 5 years survival for the Ia stage was 82.6%, 89.3% for the Ib stage, 67.8% for the II stage, 56.6% for the IIIa, 16.8% for the IIIb and 0% for the IV stage.
  • CONCLUSIONS: The relation between long distance survival and extension of the lymphadenectomy in the patients with gastric adenocarcinoma is still being discussed.
  • Different studies show the importance of a careful lymphadenectomy as the main mean for a better long distance survival in the patients with gastric cancer.
  • Other studies showed a link between gastric cancer prognosis and number of positive nodes.
  • Therefore the presence of nod metastasis has a negative influence in the prognosis of this tumor; for this reason D2 lymphadenectomy is the technique to be used for the treatment of the gastric adenocarcinoma, both for a good staging and a better long distance survival, but particularly in the advanced cancers which are, at the moment, the highest number of cases that reach the surgeon's attention.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437920.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Zhao AG, Cao W, Xu Y, Zhao G, Liu BY, Cai Y, Yang JZ, Gu Y, Yuan W, Zhu YJ, Han YY, Yang JY: [Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer]. Zhong Xi Yi Jie He Xue Bao; 2010 Mar;8(3):224-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer].
  • BACKGROUND: Gastric cancer is one of the most common malignant tumors.
  • Traditional Chinese medicine (TCM) has been widely used in treatment of gastric cancer, but still lacking large sample controlled trial to evaluate its efficacy.
  • OBJECTIVE: To analyze the prognostic factors of 220 elderly patients with gastric cancer, and to further study the efficacy of an herbal formula for invigorating spleen and it modifications based on syndrome differentiation of TCM in treatment of gastric cancer in elderly patients and the influence on prognosis.
  • DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 220 elderly patients aged 65 years or over with gastric cancer from Longhua Hospital of Shanghai University of Traditional Chinese Medicine, and Renji Hospital and Ruijin Hospital of Shanghai Jiao Tong University Medical College were prospectively enrolled.
  • Kaplan-Meier curves were used to assess the differences in survival time between TCHM group and non-TCHM group after stratification for TNM stage, surgery or chemotherapy.
  • RESULTS: The 220 eligible patients were histologically confirmed adenocarcinoma of the stomach from 2001 to 2007.
  • Cox regression analysis suggested that the TNM stage, radical resection, three or more treatment cycles of chemotherapy, and TCHM treatment were independent prognostic factors (P<0.01).
  • In stratification analysis of stage for 96 patients who did not accepted radical resection or suffered from recurrence and metastasis (36 cases in the TCHM group, and 60 cases in the non-TCHM group), Cox regression analysis suggested that three or more treatment cycles of chemotherapy and TCHM treatment were independent prognostic factors for improving survival respectively (P<0.01).
  • The hazard ratio [Exp(beta)] of TCHM in stratification for late stage was 0.421, and 95% confidence interval was from 0.255 to 0.693.
  • CONCLUSION: The herbal formula for invigorating spleen has an important value for improving the prognosis of elderly patients with gastric cancer.
  • This herbal formula show survival benefit for advanced gastric cancer in elderly patients.
  • The influence of TCHM on disease-free survival and overall survival of postoperative gastric cancer in elderly patients need to be further evaluated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Drugs, Chinese Herbal / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20226143.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


12. Chen L, Tian H, Chen J, He ZG, Tao SF, Lokesh G, Peng SY: Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B; 2005 Jan;6(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of gastric stump cancer: a report of 37 cases.
  • OBJECTIVE: To observe the clinicopathological characteristics of gastric stump cancer (GSC) and evaluate the benefits of radical surgery of GSC.
  • Twenty-one cases that received radical resection were analyzed based on the pTMN stage.
  • RESULTS: Most GSC (32/37) was detected in patients who had received Billroth II reconstruction after partial gastrectomy for benign gastric disease.
  • Differentiated adenocarcinoma was the dominant histopathological type (24/37).
  • The postoperative 5-year survival rate of early stage GSC patients (n=9) was significantly higher than advanced stage GSC (n=12) (55.6% vs 16.5%, xL2=11.48, P<0.01).
  • Five-year survival rate of 21 GSC patients with radical resection were 75% (3/4) for stage I, 60% (3/5) for stage II, 14.2% (1/7) for stage III, and 0% (0/5) for stage IV respectively.
  • The median survival time of 21 GSC patients who underwent radical resection was longer than those undergoing palliative operation (43.0 m vs 13.0 m, x L2=36.31, P<0.01), the median survival time of stage IV patients with radical resection was 23.8 months.
  • Even in stage IV GSC, radical resection can still prolong the survival time.
  • It is necessary for the patients with benign gastric diseases who received partial gastrectomy to carry out the endoscopy follow-up, especially in patients with Billroth II reconstruction procedure at 15-20 years.
  • [MeSH-major] Gastrectomy / mortality. Gastric Stump / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2001 Dec;15(12):1488 [11965473.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):580-4 [11995502.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] World J Surg. 2003 May;27(5):567-70 [12715225.001]
  • [Cites] Gut. 1987 Aug;28(8):924-8 [3666558.001]
  • [Cites] Gut. 1988 Mar;29(3):298-301 [3356360.001]
  • [Cites] Ann Surg. 1996 Jun;223(6):701-6; discussion 706-8 [8645043.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):299-301 [9058163.001]
  • [Cites] Gut. 1998 Sep;43(3):342-4 [9863478.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):188-94 [10674609.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2197-201 [10928177.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • (PMID = 15593390.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC1390757
  •  go-up   go-down


13. Sheng SL, Bao SH, Huang G, Wang LM: Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours. Clin Exp Immunol; 2008 Mar;151(3):459-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours.
  • A highly sensitive and accurate time-resolved immunofluorometric assay (TR-IFMA) has been developed, for the first time, to measure plasma vascular endothelial growth factor (VEGF) in patients with gastric tumours.
  • Plasma VEGF concentrations were measured by TR-IFMA in 92 healthy controls, in 36 benign stomach disease patients and in 92 gastric cancer patients before surgery.
  • The plasma levels of VEGF are higher in gastric cancer patients than in healthy controls.
  • VEGF levels were associated significantly with the presence of distant metastases, as well as invasion depth of the tumour and tumour stage, but not with tumour location, tumour histology, differentiation or the presence of lymph node metastases.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Stomach Neoplasms / blood. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):12-21 [16139825.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):106-11 [17321510.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1004-8 [10737380.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Circulation. 2000 Jul 11;102(2):185-90 [10889129.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):97-103 [12507965.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):215-25 [12668286.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):435-9 [14719080.001]
  • [Cites] Steroids. 2004 Jul;69(7):461-71 [15246776.001]
  • [Cites] Clin Chem. 1983 Jan;29(1):65-8 [6336682.001]
  • [Cites] Nature. 1983 Jan 20;301(5897):258-60 [6337344.001]
  • [Cites] Anal Biochem. 1984 Mar;137(2):335-43 [6375455.001]
  • [Cites] Clin Chem. 1987 Nov;33(11):1994-9 [3119252.001]
  • [Cites] Clin Biochem. 1988 Jun;21(3):139-50 [3292080.001]
  • [Cites] Clin Chem. 1990 Aug;36(8 Pt 1):1497-502 [1696856.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] J Cell Biochem. 1991 Nov;47(3):211-8 [1791185.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Pharmacol Ther. 1995 May;66(2):207-35 [7667396.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Ann Clin Biochem. 1997 May;34 ( Pt 3):276-80 [9158825.001]
  • [Cites] J Immunol Methods. 1998 Oct 1;219(1-2):45-55 [9831387.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • (PMID = 18234057.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2276956
  •  go-up   go-down


14. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res; 2008 Dec 1;14(23):7843-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of HER3 is associated with a decreased survival in gastric cancer.
  • BACKGROUND: The role of human epidermal growth factor receptor (HER) 3 and HER4 has been elucidated in gastric cancer.
  • This study investigated the positive correlation between HER1 and HER4 expression and the prognosis of patients with gastric cancers.
  • EXPERIMENTAL DESIGN: Tumor samples were obtained from gastric adenocarcinomas of 134 patients who underwent a gastrectomy from 1999 to 2002.
  • RESULTS: HER3 expression was significantly associated with parameters involved with tumor progression, including the depth of tumor invasion (T1 versus T2-T4; P = 0.000), involved lymph nodes (P = 0.000), distant metastasis (P = 0.008), tumor stage (P = 0.000), and recurrent disease (P = 0.000).
  • CONCLUSIONS: HER3 overexpression is strongly associated with tumor progression and poor prognosis of patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Receptor, ErbB-3 / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology


15. Li JT, Fu L, Xia JC, Feng BJ, Mai SJ, Yu XJ, Huang LX, Feng QS, Pan ZZ, Zhan YQ: [Minimal commonly deleted regions on chromosome 7q31 in primary gastric carcinoma and its clinical significance]. Ai Zheng; 2005 Nov;24(11):1306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimal commonly deleted regions on chromosome 7q31 in primary gastric carcinoma and its clinical significance].
  • BACKGROUND & OBJECTIVE: Previous studies have showed that chromosome 7q occurs a high frequency of loss of heterozygosity (LOH) in primary gastric carcinoma; D7S486 located in 7q31 is a locus with the highest frequency of LOH on 7q, which is significantly related to lymph node metastasis of tumor.
  • Gastric carcinoma-related tumor suppressor genes (TSGs) might locate near the locus.
  • In order to seek gastric carcinoma-related TSGs in a further narrow region, LOH of microsatellite marker loci on chromosome 7q31 was examined in primary gastric carcinoma to determine the minimal commonly deleted regions, and the possible roles of these regional deletions in gastric carcinoma pathogenesis were analyzed in this study.
  • DNAs were extracted from 78 specimens of gastric carcinoma and corresponding normal gastric mucosa tissues, amplified through multi-polymerase chain reaction (multi-PCR), and separated by electrophoresis.
  • The possible roles of these regional deletions in gastric carcinoma pathogenesis were analyzed with consideration of clinicopathologic parameters.
  • RESULTS: LOH of all 12 selected microsatellite marker loci was detected in primary gastric carcinoma, with the total frequency of 41.7% (40/72).
  • Two minimal commonly deleted regions, D7S2543-D7S486 and D7S480-D7S650 (each span about 90 kb), were detected on 7q31 in primary gastric carcinoma.
  • The LOH frequency of D7S2543-D7S486 region was significantly related to clinical stage and lymph node metastasis (P = 0.01, P = 0.03); the LOH frequency of D7S480-D7S650 region was significantly related to clinical stage (P = 0.03), and LOH of this region occurred only in the patients with stage III/IV tumor, T3/T4 primary lesion, or lymph node metastasis.
  • CONCLUSIONS: There are 2 minimal commonly deleted regions on 7q31 in primary gastric crcinoma, D7S2543-D7S486 and D7S480-D7S650.
  • There might be TSGs in these 2 regions closely related to the progression of gastric carcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. DNA, Neoplasm / genetics. Female. Humans. Lymphatic Metastasis. Male. Microsatellite Repeats. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552953.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


16. Ando H, Aihara R, Ohno T, Ogata K, Mochiki E, Kuwano H: Prognostic significance of the expression of MUC1 and collagen type IV in advanced gastric carcinoma. Br J Surg; 2009 Aug;96(8):901-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the expression of MUC1 and collagen type IV in advanced gastric carcinoma.
  • BACKGROUND: Scirrhous gastric carcinoma is characterized by excessive deposition of collagen in the stroma.
  • The aim of this study was to examine the fibrotic mechanism in several histological types of gastric carcinoma, and the combination of MUC1 and collagen type IV as a possible predictor of patient survival.
  • METHODS: One hundred and two paraffin-embedded specimens of gastric carcinoma were examined by immunohistochemical staining using monoclonal antibodies against collagen type IV and MUC1.
  • RESULTS: Collagen type IV-positive expression was significantly associated with depth of wall penetration (P = 0.025) and stage (P = 0.023).
  • CONCLUSION: In patients with differentiated-type advanced gastric carcinoma, the combination of MUC1-positive and interstitial collagen type IV-negative expression may be a marker of unfavourable prognosis.
  • [MeSH-major] Adenocarcinoma / mortality. Biomarkers, Tumor / metabolism. Collagen Type IV / metabolism. Mucin-1 / metabolism. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19591170.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Mucin-1
  •  go-up   go-down


17. Wada Y, Yoshida K, Hihara J, Tanabe K, Ukon K: Kidney metastasis of resected early gastric carcinoma: report of a case. Surg Today; 2007;37(3):248-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney metastasis of resected early gastric carcinoma: report of a case.
  • We report a rare case of kidney metastasis of resected early gastric cancer in a 67-year-old man.
  • We performed distal gastrectomy with D2 lymph node dissection for early gastric cancer, which was histologically diagnosed as moderately differentiated adenocarcinoma (T1N0M0, stage IA).
  • However, 1 year 10 months after the operation, we performed partial kidney resection and the lesion was confirmed to be a metastasis of the gastric cancer.
  • This case illustrates the poor prognosis associated with a high preoperative serum CEA level, even if early gastric cancer is resected curatively.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoembryonic Antigen / blood. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1975 Jul;114(1):30-2 [1142495.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1701-8 [12820444.001]
  • [Cites] Br J Cancer. 1982 May;45(5):718-27 [7082557.001]
  • [Cites] Jpn J Surg. 1987 Jul;17(4):269-75 [3682435.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Cancer. 1975 Dec;36(6 Suppl):2460-8 [764963.001]
  • [Cites] Gastric Cancer. 2003;6(3):142-5 [14520526.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1865-78 [11251019.001]
  • [Cites] Am J Gastroenterol. 1996 Jan;91(1):49-53 [8561143.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • (PMID = 17342368.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


18. Linder N, Haglund C, Lundin M, Nordling S, Ristimäki A, Kokkola A, Mrena J, Wiksten JP, Lundin J: Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol; 2006 Sep;59(9):965-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer.
  • AIM: To assess the clinical relevance of XOR expression in gastric cancer.
  • METHODS: XOR levels were studied by immunohistochemistry in tissue microarray specimens of 337 patients with gastric cancer and the relation between XOR expression and a series of clinicopathological variables, as well as disease-specific survival, was assessed.
  • Decreased XOR was associated with advanced stage, deep tumour penetration, diffusely spread tumour location, positive lymph node status, large tumour size, non-curative disease, cellular aneuploidy, high S-phase fraction and high cyclooxygenase-2 expression, but not with p53 expression or Borrmann classification.
  • Down regulation of XOR was associated with unfavourable outcome, and the cumulative 5-year gastric cancer-specific survival in patients with strong XOR expression was 47%, compared with 22% in those with moderate to negative expression (p<0.001).
  • This was also true in patients with stage I-II (p = 0.01) and lymph node-negative (p = 0.02) disease, as well as in patients with smaller (< or =5 cm) tumours (p = 0.02).
  • CONCLUSION: XOR expression in gastric cancer may be a new marker for a more aggressive gastric cancer biology, similar to that previously reported for breast cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Stomach Neoplasms / enzymology. Xanthine Oxidase / metabolism
  • [MeSH-minor] Aged. Cytoplasm / enzymology. Female. Follow-Up Studies. Gastric Mucosa / enzymology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Protein Array Analysis / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4372-81 [15958620.001]
  • [Cites] Genes Dev. 2002 Dec 15;16(24):3223-35 [12502743.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jul;285(1):C48-55 [12637268.001]
  • [Cites] FEBS Lett. 1975 Nov 15;59(2):245-9 [179860.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4639-46 [187329.001]
  • [Cites] Life Sci. 1978 Aug 21;23(7):729-36 [692291.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):854-9 [7459871.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3838-41 [3460692.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):197-202 [1370294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3362-6 [1314387.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1789-97 [8046245.001]
  • [Cites] Cytogenet Cell Genet. 1995;68(1-2):61-3 [7956361.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):48-56 [8569197.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):215-20 [8664030.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2923-6 [9329565.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Lab Invest. 1999 Aug;79(8):967-74 [10462034.001]
  • [Cites] Nature. 1957 Oct 12;180(4589):763-4 [13477276.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2079-85 [12190180.001]
  • (PMID = 16935971.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.17.3.2 / Xanthine Oxidase
  • [Other-IDs] NLM/ PMC1860491
  •  go-up   go-down


19. Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS: Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol; 2010 Dec;40(12):1147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients.
  • However, there are limited data regarding the clinical and prognostic significance of serum vascular endothelial growth factor levels per platelet count in unresectable advanced gastric cancer compared with early gastric cancer and healthy volunteers.
  • METHODS: A total of 181 gastric cancer patients were included and control serum samples were acquired from 113 healthy volunteers.
  • Survival curves were calculated using the Kaplan-Meier method and survival comparisons were made by the log-rank test in metastatic gastric cancer.
  • RESULTS: There was a significant correlation between serum vascular endothelial growth factor levels and differentiation of tumor (P = 0.014), stage (P = 0.036).
  • CONCLUSIONS: This study demonstrates that serum vascular endothelial growth factor per platelet count is correlated with poor overall survival and progression-free survival in patients with advanced gastric cancer.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / secondary. Case-Control Studies. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Korea. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Research Design. Retrospective Studies. Vascular Endothelial Growth Factor C / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647232.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


20. Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O: Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg; 2009 Jan;33(1):95-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.
  • BACKGROUND: We clarified the incidence of adenocarcinoma of the esophagogastric junction (AEG) at a Japanese high-volume cancer center and its clinicopathological features between the Siewert subtypes.
  • METHODS: Patients with AEG were selected from a prospective database of gastric and esophageal tumors established by Kanagawa Cancer Center.
  • RESULTS: From January 1986 to December 2005, 147 (4.0%) patients were determined to have AEG; 2,794 (75.8%) were diagnosed to be true gastric cancer, whereas 745 (20.2%) were true esophageal cancer.
  • Although the 5-year survival rate was significantly higher in type II than in type III tumors, the survival difference disappeared when the patients were restricted to an R0 resection, even though type III patients demonstrated a more advanced stage.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1035-40 [11996237.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2555-9 [11135215.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] World J Surg. 2003 Mar;27(3):334-8 [12607062.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surgery. 1998 Feb;123(2):127-30 [9481396.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] World J Surg. 2006 Mar;30(3):364-71 [16485063.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):381-8; discussion 388-9 [7512326.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):594-601 [10589596.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Surgery. 1998 Oct;124(4):707-13; discussion 713-4 [9780992.001]
  • (PMID = 18958523.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Coşkun U, Akyürek N, Dursun A, Yamaç D: Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma. J Surg Res; 2010 Nov;164(1):110-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma.
  • The aim of the present study was to evaluate the clinical significance of lymphangiogenesis and its regulation in gastric carcinomas.
  • METHODS: The lymphatic vessel density (LVD) in 65 gastric carcinoma cases was investigated by immunohistochemistry using D2-40 antibody, and evaluated with prognostic parameters.
  • The peritumoral LVD significantly correlated with large tumor size (P=0.0001), lymph node metastasis (P=0.004), visceral organ metastasis (P=0.0001), and TNM stage (P=0.001).
  • CONCLUSION: Our study showed that lymphangiogenesis plays an important role in the progression of gastric carcinoma.
  • Therefore, D2-40, as an indicator for tumor lymphangiogenesis, may serve as a prognostic marker in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Lymphangioma / pathology. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19628230.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Oza A, Brierley J, Swallow C, Cummings B, Knox JJ, Kim J, Wong R, Siu L, Feld R, Ringash J: Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. Curr Oncol; 2010 Aug;17(4):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study.
  • OBJECTIVE: This phase I study aimed to determine the maximal tolerated dose of cisplatin administered every 2 weeks with infusional 5-fluorouracil (5FU) and concurrent radiation therapy (RT) in patients after complete resection of gastric adenocarcinoma.
  • METHODS: Patients with resected stage IB to IV (M0) gastric adenocarcinoma were treated with 12 weeks of infusional 5FU (200 mg/m(2) daily) and with RT (45 Gy in 25 fractions starting on day 16).
  • CONCLUSIONS: Cisplatin was well tolerated in combination with infusional 5FU and RT, showing promising activity in the adjuvant treatment of gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] ANZ J Surg. 2004 Nov;74(11):951-6 [15550081.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):777-82 [9128951.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):277-84 [8996153.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1433-8 [14562013.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1373-7 [12954575.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1069-75 [12419433.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):712-6 [17848909.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):713-9 [16626887.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):603-7 [16489675.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):732-8 [15978742.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1326-33 [15919686.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(2):CD004064 [15846694.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • (PMID = 20697512.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2913826
  • [Keywords] NOTNLM ; 5-fluorouracil / Adjuvant therapy / chemoradiation / cisplatin / gastric cancer / phase i study
  •  go-up   go-down


23. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH: Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer; 2005 Jun 1;103(11):2383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
  • BACKGROUND: Positron emission tomography (PET) with 18- fluorodeoxyglucose (FDG) has been used to both detect and stage a variety of malignancies.
  • The current study examined the value of PET for preoperative staging of gastric adenocarcinoma.
  • METHODS: Sixty-eight patients (49 males and 19 females) with gastric adenocarcinoma, who were referred for preoperative FDG-PET scans, were enrolled in this study.
  • RESULTS: For the primary tumor of a gastric adenocarcinoma, PET demonstrated an increased uptake in 64 of 68 patients (sensitivity, 94%), with a mean SUV of 7.0 (range, 0.9-27.7).
  • A comparison of FDG uptake and clinicopathologic features showed significant association between FDG uptake and macroscopic type, tumor size, lymph node metastasis, histologic type, and TNM stage.
  • CONCLUSIONS: FDG-PET improves the preoperative TNM staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856477.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A: PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues. Hepatogastroenterology; 2008 Jul-Aug;55(85):1480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues.
  • BACKGROUND/AIMS: To investigate the mechanism of PAI-1 overexpression in gastric cancers, the PAI-1 expression levels in gastric cancers were compared to those in the corresponding normal tissues.
  • METHODOLOGY: A quantitative RT-PCR for PAI-1 gene was performed in gastric cancers and corresponding normal tissues, and evaluated the association between the PAI-1 expression levels in gastric cancers and those in corresponding normal tissues.
  • RESULTS: There was a significant correlation between gastric cancer and corresponding normal PAI-1 expressions with a Spearman's rank correlation coefficient of 0.74 (p < 0.0001).
  • PAI-1 expression levels in corresponding normal tissues increased significantly with tumor stage [stage I, -8.04 +/- 0.72; stage II, -7.71 +/- 0.61: stage III, -6.81 +/- 0.51; stage IV, -4.95 +/- 0.20 (p = 0.0022)).
  • CONCLUSIONS: Previous studies found that PAI-1 overexpression was significantly associated with malignancy of gastric cancers.
  • Taken together, PAI-1 overexpression in gastric cancers might be originated from higher PAI-1 expression in corresponding normal tissues and result in a malignant phenotype of these cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Plasminogen Activator Inhibitor 1 / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795717.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / SERPINE1 protein, human
  •  go-up   go-down


25. Hitomi G, Watanabe H, Tominaga K, Yoshitake N, Suzuki M, Maeda M, Yamagata M, Kanke K, Nakamura T, Masuyama H, Hiraishi H: Endoscopic submucosal dissection in 100 lesions with early gastric carcinoma. Hepatogastroenterology; 2009 Jan-Feb;56(89):254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection in 100 lesions with early gastric carcinoma.
  • BACKGROUND/AIMS: ESD is a new diagnostic and treatment technique for early gastric cancer.
  • METHODOLOGY: The subject group included 95 patients with 100 early-stage gastric cancers.
  • According to the Gastric Cancer Treatment Guidelines published by the Japanease Gastric Cancer Association (JGCA) in 2001.
  • Sixty-seven lesions presented a tumor measuring less than 20 mm and were concave (if not flat) without ulceration (specified indication of the guidelines of the Japanese Gastric Cancer Association), and 33 lesions were expanded indications.
  • We then compared one-piece resection rates, en-bloc resection rates (one-piece resection that is lateral- and vertical-stump negative), curative en-bloc resection rates (en-bloc resection that fulfills the following three criteria: 1. differentiated adenocarcinoma; 2. no lymphtic or venous invasion, 3a. intramucosal cancer regardless of tumor size without ulceration, 3b. intramucosal cancer 30 mm in size with ulceration, 3c. minute submucosal cancer 30 mm in size).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453070.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, Turhal S: Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications. Pathol Oncol Res; 2007;13(3):215-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications.
  • The presence of neuroendocrine (NE) cells in gastric adenocarcinoma (GCa) is well documented, however, their significance is controversial.
  • 101 partial or total gastrectomy specimens from patients operated for conventional gastric adenocarcinoma were included in the study.
  • Among histopathologic variables, the presence of NE cells was significantly related to grade, stage and lymph node status.
  • The results of our study suggest that the presence of NE cells may have an effect on the expression of TGF-alpha and EGFR in GCa, and the autocrine mechanism between TGF-alpha and EGFR plays an important role in the prognosis of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Neurosecretory Systems / pathology. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / metabolism. Transforming Growth Factor alpha / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2002 Feb;110(2):132-9 [12064868.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):858-61 [12679948.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):327-33 [9060603.001]
  • [Cites] Jpn J Cancer Res. 1990 Jan;81(1):43-51 [2108945.001]
  • [Cites] Cell. 1984 Jun;37(2):357-8 [6327062.001]
  • [Cites] Cancer. 1983 May 1;51(9):1673-81 [6187432.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] Cell. 1989 Oct 6;59(1):33-43 [2790960.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):324-31 [14991403.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):189-94 [1349007.001]
  • [Cites] Histochem J. 2000 Sep;32(9):551-6 [11127976.001]
  • [Cites] APMIS. 2003 Oct;111(10):931-9 [14616544.001]
  • [Cites] Scand J Gastroenterol. 1992;27(2):155-60 [1561530.001]
  • [Cites] Virchows Arch. 2002 Jan;440(1):85-93 [11942581.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):325-35 [10461363.001]
  • [Cites] J Neuroendocrinol. 2006 May;18(5):355-60 [16629834.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1096-104 [3044573.001]
  • [Cites] Histopathology. 1986 Jan;10(1):53-63 [2420694.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):681-5 [1592392.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):283-8 [8615622.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] J Cell Biochem. 1986;32(4):293-304 [3543030.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1329-35 [15920550.001]
  • [Cites] Annu Rev Biochem. 1984;53:259-92 [6089648.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(2):121-31 [2157713.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Prostate Suppl. 1998;8:74-9 [9690666.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):783-810 [8780586.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1212-23 [8898635.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):47-51 [15029262.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):645-51 [7860139.001]
  • [Cites] Cancer. 1971 Feb;27(2):447-54 [4322466.001]
  • [Cites] Hum Pathol. 1994 Nov;25(11):1114-22 [7959656.001]
  • [Cites] J Pathol. 1993 Feb;169(2):191-201 [8445485.001]
  • [Cites] Oncology. 1992;49(2):157-61 [1574253.001]
  • [Cites] Am J Pathol. 1984 Jun;115(3):458-68 [6375394.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):435-44 [9690535.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):133-7 [8321742.001]
  • (PMID = 17922051.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Gastrins; 0 / Transforming Growth Factor alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


27. Cappell MS: Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases. Am J Gastroenterol; 2007 Jun;102(6):1307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologically proven stomal metastases were located in the abdominal wall (PEG exit site) in 63%, in the gastric wall (PEG entrance site) in 7%, and in both walls in 30%.
  • (b) squamous cell histology (in 98%, adenocarcinoma in 2%);.
  • (d) advanced pathologic stage (in 97%, early stage in 3%); and (e) large primary cancer size at diagnosis (mean diameter 4.2+/-2.3 cm).
  • CONCLUSIONS: Strong risk factors for stomal metastases include: pharyngoesophageal primary cancer, squamous cell histology, less well-differentiated cancer, large size, and advanced cancer stage.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488255.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
  • BACKGROUND: MK-1, the target molecule of FU-MK-1, is encoded by the GA733-2 gene, which is currently being used as a target in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies.
  • Also of interest is p53, a protein that has been intensively investigated in relation to particular types of tumors, patterns of metastases, tumor stage, and prognosis.
  • METHODS: The expression of p53 protein and MK-1 antigen was investigated in specimens from 42 patients with gastric carcinoma.
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • Most patients with p53- and MK-1-positive gastric carcinomas and those more than five metastatic lymph nodes had a poor prognosis.
  • CONCLUSION: The study found that the expression of both p53 and MK-1 was frequent in aggressive gastric carcinomas; however, extensive lymph node involvement (more than five nodes) was the only significant factor related to overall survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(4):343-7 [8205349.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):211-6 [16616808.001]
  • [Cites] Arch Pathol Lab Med. 1977 Nov;101(11):568-71 [334106.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2649-55 [7538044.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):653-61 [8398688.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):231-8 [10761711.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Virchows Arch. 1994;424(2):187-93 [8180781.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):769-76 [12014649.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2001-7 [12174877.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3952-6 [6744310.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):174-86 [8424417.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2439-47 [7680948.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2443-50 [1933781.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Histopathology. 2004 Apr;44(4):323-31 [15049897.001]
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Milano MT, Garofalo MC, Chmura SJ, Farrey K, Rash C, Heimann R, Jani AB: Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol; 2006 Jun;79(942):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
  • The purpose of this study was to assess the efficacy and toxicity of intensity-modulated radiation therapy (IMRT) in the treatment of gastric cancer.
  • Seven patients with gastric cancer were treated with IMRT.
  • Six patients (all Stage III) received post-operative chemoradiotherapy with concurrent 5-fluorouracil and leucovorin.
  • IMRT in the treatment of gastric malignancies reduces the mean and above threshold doses to critical normal tissues.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Radiotherapy, Intensity-Modulated / methods. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714752.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Nakayama T, Hirakawa H, Shibata K, Abe K, Nagayasu T, Taguchi T: Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. Oncol Rep; 2010 Sep;24(3):599-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion.
  • To elucidate ANGPTL4 expression and its association with clinicopathological factors and prognosis in human gastric adenocarcinomas, we examined 103 cases of surgically-resected human gastric adenocarcinoma by immunohistochemistry.
  • Among 103 cases of adenocarcinoma, 38 cases (36.9%) showed positive staining in the cytoplasm of the carcinoma cells for ANGPTL4.
  • The expression of ANGPTL4 was correlated with the depth of tumour invasion (p<0.005), lymph node metastasis (p<0.001), venous invasion (p<0.00005) and TNM stage (p<0.001) in the total carcinoma.
  • RT-PCR or Western blot analysis showed the expression of mRNA or protein of ANGPTL4 in all four surgically-resected samples and all four cell lines of human gastric adenocarcinoma.
  • These findings suggest that the ANGPTL4 is one of the factors involved in the progression of human gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Angiopoietins / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism. Veins / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664963.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ANGPTL4 protein, human; 0 / Angiopoietins; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


31. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients had pathological stage IA, one patient each had stage IB and IIA, five patients had stage IIIA, and one patient stage IIIB.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


32. Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N: Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma. Br J Surg; 2008 Jul;95(7):840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Of 790 patients with oesophageal carcinoma staged between December 2000 and December 2004, 189 were eligible for potentially curative treatment. (99m)Tc-labelled hydroxymethylene diphosphonate bone scintigraphy was performed in those with stage T3 N1 disease (identified by computed tomography and endoscopic ultrasonography) who were suitable for radical treatment.
  • The histological diagnosis was adenocarcinoma in 82 patients and squamous cell carcinoma in 33.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 18551472.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


33. Ahn HS, Lee HJ, Hahn S, Kim WH, Lee KU, Sano T, Edge SB, Yang HK: Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer; 2010 Dec 15;116(24):5592-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification.
  • BACKGROUND: The seventh TNM staging system for gastric cancer of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) had a more detailed classification than the sixth TNM staging system for both the tumor (T) and lymph nodes (N).
  • METHODS: The authors analyzed the prospectively collected database on patients with gastric cancer who underwent surgery at Seoul National University Hospital between 1986 and 2006, and calculated the survival rates of 9998 cases with primary cancer, R0 resection, and >14 retrieved lymph nodes.
  • The 5YSR according to seventh edition of the TNM staging system were 95.1% (stage IA), 88.4% (stage IB), 84.0% (stage IIA), 71.7% (stage IIB), 58.4% (stage IIIA), 41.3% (stage IIIB), and 26.1% (stage IIIC), which were significantly different from each other.
  • Each stage in the sixth edition was divided into the seventh edition stage with different survival rates.
  • [MeSH-major] Adenocarcinoma / classification. Neoplasm Staging / standards. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [CommentIn] Cancer. 2011 Jun 15;117(12):2823-4; author reply 2824 [21264825.001]
  • (PMID = 20737569.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G, Gruppo Oncologico Italia Meridionale: Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol; 2007 Aug;18(8):1354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
  • BACKGROUND: This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients.
  • PATIENTS AND METHODS: From June 1996 to June 2001, 228 stage IB-IIIB gastric cancer patients were enrolled.
  • CONCLUSIONS: In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525087.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Wu J, Zhou HF, Wang CH, Zhang B, Liu D, Wang W, Sui GJ: [Decreased expression of Cx32 and Cx43 and their function of gap junction intercellular communication in gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Decreased expression of Cx32 and Cx43 and their function of gap junction intercellular communication in gastric cancer].
  • OBJECTIVE: The aim of this study was to investigate the expression of connexin (Cx) and the function of gap junction intercellular communication (GJIC) in the carcinogenesis, progression and metastasis of gastric cancers.
  • Indirect immunofluorescence assay was used to investigate the expression of Cx32 and Cx43 proteins in several gastric cancer lines of various differentiation grades.
  • The expression of Cx43 in samples of gastric cancer tissue, adjacent normal tissue and in the gastric cancer cell lines of various differentiation grades was detected by Western blot.
  • RESULTS: In the normal gastric mucosa the expression rates of both Cx32 and Cx43 were 100%.
  • In gastric cancers, the expression rates of Cx32 andCx43 were 49.5% (55/111) and 39.6% (44/111), respectively.
  • Cx43 expression was significantly associated with the TMN stage, histological type, depth of infiltration and distant metastasis (P < 0.05), but Cx32 expression was not significantly correlated with depth of infiltration ( P > 0.05).
  • Western blotting showed that Cx43 expression in normal tissue was higher than that in gastric cancer tissue, and in the cell lines GES-1, N87 and BGC-823, the bands seemed decreasing progressively.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Cell Line, Tumor. Down-Regulation. Female. Gastric Mucosa / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396685.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Connexin 43; 0 / Connexins; 0 / connexin 32
  •  go-up   go-down


36. Zhang J, Ji J, Yuan F, Chen J, Yan M, Yu YY, Liu BY, Yin HR, Lin YZ, Zhu ZG: [Transcription factor Sp1 expression in gastric cancer and its prognostic value]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):531-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transcription factor Sp1 expression in gastric cancer and its prognostic value].
  • OBJECTIVE: To investigate the expression of transcription factor Sp1 in human gastric cancer tissues and normal gastric mucosa, and its prognostic significance.
  • METHODS: By using immunohistochemistry, we studied the Sp1 expression patterns in 65 cases of gastric cancer with various clinico-pathologic characteristics, and 40 normal gastric mucosa specimens obtained from patients who underwent partial gastrectomy for benign gastric diseases.
  • RESULTS: The expression rate of Sp1 in normal gastric mucosa was 12.5% (5/40).
  • In sharp contrast, Sp1 expression rate in gastric cancer lesions was 53.8% (35/65).
  • Sp1 protein expression was closely related to the depth of tumor invasion and TNM stage (P = 0.001, P = 0.026), but not related to the number of metastatic lymph nodes and Lauren's classification (P = 0.306, P = 0.667).
  • CONCLUSION: Normal and malignant gastric tissues have unique Sp1 expression patterns.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Sp1 Transcription Factor / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Gastric Mucosa / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438849.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Sp1 Transcription Factor
  •  go-up   go-down


37. Firat O, Guler A, Sozbilen M, Ersin S, Kaplan H: Gastric remnant cancer: an old problem with novel concerns. Langenbecks Arch Surg; 2009 Jan;394(1):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric remnant cancer: an old problem with novel concerns.
  • BACKGROUND AND AIMS: The patients with cancers in the remnant stomachs after previous partial resections for benign diseases constitute a peculiar subset of the patients with gastric cancer.
  • Clinicopathologic features such as age, gender, time interval between the initial operation and diagnosis of gastric remnant cancer, preoperative symptoms, surgical management, and tumor characteristics like size, location, histopathology, depth of invasion, lymph node involvement, presence of distant metastasis, and stages were documented.
  • CONCLUSION: Curative resection has to be the goal of surgical management in patients with gastric remnant cancer.
  • Concerning clinician should be sceptical about a newly developing cancer in order to detect it in an early stage and enhance resectability.
  • [MeSH-major] Gastrectomy. Gastric Stump / surgery. Stomach Diseases / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Aged. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2003 Apr;82(4):241-6 [12672008.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1A):231-5 [9568082.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):133-9 [17071041.001]
  • [Cites] Gastric Cancer. 2002;5(1):16-22 [12021855.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):727-33 [17960625.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1191-4 [16797159.001]
  • [Cites] Am J Surg. 2007 Aug;194(2):143-7 [17618792.001]
  • [Cites] Ann Surg. 1922 Sep;76(3):405-8 [17864703.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2643-7 [10522057.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1747-51 [7634399.001]
  • [Cites] Br J Surg. 2007 Jan;94(1):92-5 [17054314.001]
  • [Cites] Am J Surg. 1997 Apr;173(4):292-7 [9136783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):569-72 [8268775.001]
  • [Cites] Br J Surg. 1993 Jan;80(1):54-6 [8428294.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):159-68 [9618135.001]
  • [Cites] J Surg Oncol. 1996 Oct;63(2):119-24 [8888805.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1490-6 [7889480.001]
  • [Cites] Am J Surg. 1981 Apr;141(4):487-91 [6164300.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] J Surg Oncol. 1994 Sep;57(1):22-4 [8065146.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):822-4 [1873711.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):15-21 [8275417.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):188-94 [10674609.001]
  • [Cites] Am J Surg. 2007 Jul;194(1):63-7 [17560911.001]
  • [Cites] Hepatogastroenterology. 1992 Feb;39(1):4-8 [1568706.001]
  • (PMID = 18607624.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Blackshaw G, Lewis WG, Hopper AN, Morgan MA, Al-Khyatt W, Edwards P, Roberts SA: Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer. Clin Radiol; 2008 Oct;63(10):1092-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer.
  • AIMS: To assess the strength of agreement between the perceived preoperative stage of Siewert II (oesophagogastric junction) and Siewert III (proximal gastric tumours) as determined by computed tomography (CT) and endoscopic ultrasound (EUS), both alone and in combination, with histopathological stage.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774355.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Kim YS, Heo WS, Chae KH, Gang YS, Jung JH, Kim SH, Seong JK, Lee BS, Jeong HY, Song KS, Shin KS, Cho JS, Noh SM: [Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach]. Korean J Gastroenterol; 2006 Jun;47(6):425-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 1995 to June 2005, 2,282 cases of gastric carcinoma were resected surgically in our hospital and 191 additional cases were resected by endoscopic mucosal resection.
  • RESULTS: The study consists of eight cases (0.032%) of primary squamous cell carcinoma (one case) and adenosquamous carcinoma (seven cases) without early gastric cancer.
  • The clinical presentation and physical findings did not differ from those of adenocarcinoma.
  • At the initial diagnosis, six (75%) were stage IV based on TNM tumor staging.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809949.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


40. Song SY, Son HJ, Kim MH, Nam ES, Rhee JC, Park C: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology; 2007 Apr-May;54(75):973-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of maspin expression in human gastric adenocarcinoma.
  • However, molecular aspects in carcinogenesis and progression of gastric cancer remain largely unclear.
  • Previously we reported for the first time that maspin is induced in the course of gastric carcinogenesis.
  • In the present study we evaluated maspin induction in gastric adenocarcinoma in relation to a number of clinicopathologic feature.
  • METHODOLOGY: Maspin expression was examined by Western blot analysis and immunohistochemical staining in 82 cases of gastric adenocarcinoma.
  • RESULTS: In Western blot analysis, gastric specimens of tumor showed increased maspin expression compared with corresponding normal tissues in 54 of 82 patients (66%).
  • Tumor shows increased maspin expression compared with normal tissue in 81.1% of stage IV patients and 83.3% of N3 patients.
  • The frequency of maspin induction was associated with the stage of gastric cancer (p = 0.01) and lymph node metastasis (p = 0.03).
  • CONCLUSIONS: Our data suggest that maspin may have an important role in the progression and metastasis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Serpins / analysis. Serpins / metabolism. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591106.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


41. Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HH, Lam SK, Rashid A, Wong BC, Chan AO: An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion; 2006;74(2):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer.
  • BACKGROUND: Both serum IL-6 levels and CpG island methylation have been shown to have prognostic significance in gastric cancer, it was suggested that an important link existed between IL-6 and methylation of cancers.
  • AIM: To investigate the prognostic value of IL-6 serum level and the association between serum IL-6 levels and CpG island methylation at p16, DAPK, MGMT and E-cadherin in patients with gastric cancer.
  • PATIENTS AND METHODS: Methylation status was assessed by MSP in 75 surgical specimens of gastric adenocarcinoma.
  • Serum IL-6 levels were also associated with TNM stage (p = 0.001), depth of tumor invasion (p = 0.002), lymphatic invasion (p = 0.01), vascular invasion (p = 0.008), metastasis (p = 0.002) and signet cell histology (p = 0.001).
  • CONCLUSION: IL-6 is of prognostic value for patients of gastric cancer.
  • Low serum IL-6 levels were associated with p16 or DAPK gene methylation in patients with gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139167.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cadherins; 0 / Interleukin-6; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


42. Bektas S, Bahadir B, Ucan BH, Ozdamar SO: CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res; 2010 Dec;16(4):569-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.
  • CD24 and galectin-1 expression in gastric adenocarcinoma and their clinicopathologic significance remained largely unknown.
  • We aimed to evaluate expressions and staining intensities of CD24 and galectin-1 in gastric adenocarcinoma and to investigate the interrelation with clinicopathologic parameters including survival.
  • 93 cases with gastric adenocarcinoma were reevaluated histopathologically and immunohistochemistry was performed with antibodies against CD24 and galectin-1.
  • CD24 staining intensity was associated with lymphovascular invasion (p = 0.007), serosal invasion (p = 0.001), stage (p = 0.001) and lymph node metastasis (p = 0.005).
  • Galectin-1 staining intensity in tumor-associated stromal cells was associated with tumor location (p = 0.031), lymphovascular invasion (p = 0.001), perineural invasion (p = 0.001), serosal invasion (p = 0.001), differentiation (p = 0.003), stage (p = 0.001) and lymph node metastasis (p = 0.001).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antigens, CD24 / biosynthesis. Galectin 1 / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2006;202(8):569-76 [16828238.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1849-58 [12673710.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):125-33 [19072375.001]
  • [Cites] Blood. 1997 May 1;89(9):3385-95 [9129046.001]
  • [Cites] Glycobiology. 2006 Nov;16(11):137R-157R [16840800.001]
  • [Cites] Pathol Res Pract. 2009;205(8):524-33 [19243896.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):183-92 [14716744.001]
  • [Cites] Glycoconj J. 2004;19(7-9):537-42 [14758077.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):171-5 [7622305.001]
  • [Cites] Angiogenesis. 1999;3(4):317-25 [14517411.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8932-41 [16219933.001]
  • [Cites] Cell Mol Life Sci. 2007 May;64(10):1254-8 [17364145.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):587-94 [18288388.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Urology. 2008 Sep;72(3):603-7 [18384848.001]
  • [Cites] Histol Histopathol. 2009 Mar;24(3):309-16 [19130400.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):302-10 [11274640.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):279-83 [18752058.001]
  • [Cites] Glycoconj J. 2004;19(7-9):507-15 [14758074.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):1083-9 [15477346.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10783-93 [16322224.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4 [16507407.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1215-21 [12368195.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] Glia. 2001 Mar 1;33(3):241-55 [11241742.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Sep;27(9):1331-4 [17884770.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4906-13 [14581365.001]
  • [Cites] Cancer Lett. 1999 Aug 23;143(1):87-94 [10465342.001]
  • [Cites] Dev Dyn. 2007 Apr;236(4):1014-24 [17366633.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):545-53 [18202194.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2748-58 [17680316.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):370-9 [12471620.001]
  • [Cites] J Gastrointest Surg. 2007 Apr;11(4):445-51 [17436128.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1058-67 [9028339.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2331-8 [17304502.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4717-21 [7553654.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6574-81 [16166435.001]
  • [Cites] J Cell Biol. 1990 May;110(5):1681-91 [2335567.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):377-86 [12649338.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):39-43 [9988230.001]
  • [Cites] J Histochem Cytochem. 2001 Apr;49(4):539-49 [11259457.001]
  • [Cites] BMC Cancer. 2008 Apr 24;8:118 [18433506.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):506-14 [19050962.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):255-62 [15339045.001]
  • [Cites] J Pathol. 2001 Jan;193(1):80-7 [11169519.001]
  • (PMID = 20177845.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / CD24 protein, human; 0 / Galectin 1
  •  go-up   go-down


43. Hur K, Kwak MK, Lee HJ, Park DJ, Lee HK, Lee HS, Kim WH, Michaeli D, Yang HK: Expression of gastrin and its receptor in human gastric cancer tissues. J Cancer Res Clin Oncol; 2006 Feb;132(2):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of gastrin and its receptor in human gastric cancer tissues.
  • This study was performed to investigate the prognostic significance and the expression profiles of gastrin and gastrin receptor in human gastric carcinoma tissues.
  • METHODS: We analyzed the expressions of gastrin and gastrin receptor by immunohistochemical staining using anti-gastrin Ab (Sigma, St. Louis, MO, USA) and anti-gastrin receptor Ab (Aphton Corp., Woodland, CA, USA) in 279 gastric adenocarcinoma patients.
  • Gastrin expression was significantly higher in men than in women (54.3% vs. 34.1%), and higher in differentiated gastric adenocarcinoma than in the undifferentiated type (55.1% vs. 43.0%).
  • When focused on correlation between the co-expression of gastrin and gastrin/CCKB receptor and the survival, the prognosis of patients positive for both gastrin and gastrin receptor was significantly poorer than for those negative for gastrin and gastrin receptor in diffuse-type gastric cancer patients.
  • However, multivariate analysis showed that only TNM stage was an independent prognostic factor of survival in diffuse-type gastric cancer patients.
  • CONCLUSIONS: This study shows that the expression rates of gastrin and gastrin receptor are high (about a half) in gastric carcinoma tissues, and that there is an association between gastrin and gastrin receptor expression.
  • We also found that patients with diffuse-type gastric carcinoma tissues expressing both gastrin and gastrin receptor have a poorer prognosis than those negative for both, which suggests that gastrin acts as an autocrine growth factor in a subgroup of gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Gastrins / analysis. Receptor, Cholecystokinin B / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):391-9 [3510144.001]
  • [Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]
  • [Cites] Eur J Biochem. 1993 Aug 1;215(3):513-29 [8354258.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):697-701 [10611248.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):932-7 [3338085.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):375-83 [11880476.001]
  • [Cites] Gut. 1998 Jun;42(6):795-8 [9691917.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):767-78 [1537514.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):1015-25 [9287997.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1356-70 [8482449.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):235-42 [12009231.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):554-8 [2713241.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 1):G773-84 [10516143.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):280-6 [8978369.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R277-83 [8304551.001]
  • [Cites] Am J Physiol. 1993 Feb;264(2 Pt 1):G179-86 [8447399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8691-5 [1528881.001]
  • [Cites] Pancreas. 2002 Mar;24(2):121-9 [11854616.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):33-8 [2293597.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G359-66 [11804858.001]
  • [Cites] Biopolymers. 2002;66(6):399-418 [12658727.001]
  • [Cites] Gut. 1999 Dec;45(6):812-7 [10562577.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1356-66 [11478485.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):276-85 [10982627.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605-9 [1373504.001]
  • [Cites] Physiol Rev. 1988 Apr;68(2):456-502 [3282244.001]
  • [Cites] Eur J Pharmacol. 2003 Aug 1;474(1):21-9 [12909192.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):564-8 [11298626.001]
  • [Cites] Gastroenterology. 1976 Feb;70(2):278-88 [765181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11825-30 [8876222.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):335-41 [12761477.001]
  • (PMID = 16228228.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastrins; 0 / Receptor, Cholecystokinin B
  •  go-up   go-down


44. Wen D, Shan B, Wang S, Zhang L, Wei L, Zhou W, Peng Q: A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area. Eur J Med Genet; 2010 Sep-Oct;53(5):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area.
  • BACKGROUND: To find a genetic component in gastric cardia adenocarcinomas (GCA).
  • The difference in AO and RASPUGIC between the positive and the negative FHUGIC GCAs is significant or nearly significant in most subgroups; minimizing the possibility of a false association due to bias or confounding (e.g. significant stage-specific differences in AO between familial and sporadic GCAs observed in the subgroup of T2,3N0M0 (P = 0.000) and T2,3,4N1M0 (P = 0.03) exclude the possibility of ascertainment bias towards an earlier diagnosis in familial cases), and the association between FHUGIC and RASPUGIC is statistically significant for GCAs of younger AO (<55 yr old, RASPUGIC 3.8% vs 1.6% vs 1.1% for the positive, negative and missing FHUGIC GCAs respectively, χ2 = 6.50, P = 0.04), but not significant for the later onset GCAs (≥55 yr old, RASPUGIC 2.5%, 1.1%, 1.9% for the positive, negative and missing FHUGIC respectively, χ2 = 4.22, P = 0.12).
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group. Cardia / pathology. Esophageal Neoplasms / genetics. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20603233.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med; 2006 Nov;20(9):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.
  • OBJECTIVE: Variable uptake of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has been noticed in positron emission tomography (PET) studies of gastric carcinoma patients, with low uptake occurring especially in some particular histological subtypes and early carcinomas.
  • The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors.
  • METHODS: FDG-PET was performed on 35 preoperative patients with gastric carcinoma.
  • Forty macroscopically distinguishable lesions on a surgical specimen were histologically classified into two subtypes: Cohesive type (papillary adenocarcinoma, tubular adenocarcinoma, and solid type poorly differentiated adenocarcinoma) or Noncohesive type (signet-ring cell carcinoma and non-solid type poorly differentiated carcinoma).
  • RESULTS: Nineteen of 40 gastric carcinomas showed detectable FDG uptake (48%), multiple regression analysis revealed that both the depth of invasion and histological subtypes are independent factors that influence the detectable FDG uptake in gastric carcinoma (R2 = 0.66).
  • GLUT-1 expression was seen from an early cancer stage and the cohesive type was an independent factor influencing the overexpression of GLUT-1 (R2 = 0.66).
  • GLUT-1 expression was the most influential factor for the degree of FDG uptake in gastric carcinoma (R2 = 0.68).
  • CONCLUSIONS: This study provided important information on the clinical application of FDG-PET in gastric carcinoma that early or non-cohesive gastric carcinoma may show lower FDG uptake.
  • Therefore, the usefulness of FDG-PET for the detection of gastric carcinoma is limited.
  • But there is a possibility that FDG uptake associated with GLUT-1 expression may serve as a prognostic factor of gastric carcinoma representing tumor metabolism.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fluorodeoxyglucose F18 / pharmacokinetics. Gene Expression Regulation, Neoplastic. Glucose Transporter Type 1 / biosynthesis. Positron-Emission Tomography / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294670.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.
  • The records of the patients were reviewed and the prognostic factors such as age, gender, location and size of the tumor, type of surgery, blood transfusion, depth of tumor invasion, lymph node metastases, stage of the disease, grading, vascular invasion, lymph vessel invasion, characteristics of the tumor according to Lauren's classification, and lymph node ratio were evaluated by using statistical methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


47. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer; 2010;10:218
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.
  • BACKGROUND: The relationships between the expression of CD133, Ki-67 and prognosis in gastric adenocarcinoma are unknown and needs exploring.
  • METHODS: The samples of gastric adenocarcinoma from 336 Chinese patients with follow-up were analyzed for CD133 and Ki-67 protein expressions by immunohistochemical method.
  • RESULTS: CD133 was expressed in up to 57.4% (193/336) of this group of gastric carcinoma.
  • CD133 was positive corresponded with the tumour size, grade, infiltrative depth and clinical stage (all P < 0.05).
  • The expression of CD133 has a positive correlation with that of Ki-67 (r = 0.188, P = 0.001) in gastric adenocarcinoma.
  • CONCLUSIONS: It is suggested that CD133 may play an important role in the evolution of gastric adenocarcinoma and should be considered as a potential marker for the prognosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Glycoproteins / analysis. Ki-67 Antigen / analysis. Peptides / analysis. Stomach Neoplasms / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. China. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Assessment. Time Factors. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):414-5 [15004528.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Rocz Akad Med Bialymst. 2004;49 Suppl 1:64-6 [15638377.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):61-4 [17133114.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):687-8 [17151644.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Laryngoscope. 2007 Mar;117(3):455-60 [17334305.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):149-57 [17516028.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1389-97 [18349830.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2021-4 [18497883.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):100-9 [18542072.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1212-8 [18479363.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1578-83 [18754869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:85 [19108713.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):185-93 [19026485.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] Expert Opin Ther Targets. 2009 Jul;13(7):823-37 [19530986.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2034-40 [19403300.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Cancer Treat Rev. 2009 Aug;35(5):403-8 [19369008.001]
  • [Cites] Histopathology. 2009 Sep;55(3):284-93 [19723143.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):844-50 [19626493.001]
  • [Cites] J Pathol. 2009 Dec;219(4):427-34 [19621338.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20487522.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC2891633
  •  go-up   go-down


48. Bragantini E, Barbi S, Beghelli S, Moore PS, de Manzoni G, Roviello F, Tomezzoli A, Vindigni C, Baffa R, Scarpa A: Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. J Cancer Res Clin Oncol; 2006 Jan;132(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker.
  • Several studies have reported conflicting results regarding correlations of the loss of Fhit expression with clinicopathological parameters in gastric cancer.
  • We investigated the immunohistochemical expression of Fhit in 362 cases of sporadic advanced gastric adenocarcinoma.
  • Absence of Fhit expression also correlated with tumor stage (P<0.001), lymph node involvement (P<0.001), presence of distant metastasis (P=0.033), and increasing histological grade (P=0.005).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 15;284(3):850-5 [11396980.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3173-9 [8764101.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 2002;112(1-4):39-49 [15080495.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):728-35 [11916557.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1308-14 [10096564.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1578-84 [11245468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10250-5 [11517343.001]
  • [Cites] Biochemistry. 1996 Sep 10;35(36):11529-35 [8794732.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1618-24 [10334551.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10 ):1581-8 [15196543.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8 [12669232.001]
  • [Cites] Exp Mol Med. 2001 Sep 30;33(3):124-30 [11642547.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1435-7 [9108441.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7607-12 [15569992.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):17-21 [15609389.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1768-70 [12958204.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Sep;20(1):98-102 [9290961.001]
  • [Cites] Oncology. 2001;61(3):205-11 [11574776.001]
  • [Cites] Cell. 1996 Apr 5;85(1):17-26 [8620533.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):515-23 [12702909.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):672-7 [14760383.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):24-34 [10618602.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] J Pathol. 1999 Aug;188(4):378-81 [10440747.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4708-14 [9788626.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):955-8 [9378557.001]
  • (PMID = 16217683.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


49. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP: A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol; 2006 Sep;17(9):1404-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
  • BACKGROUND: The aim of the study was to evaluate the efficacy and toxicity of neoadjuvant chemotherapy with intravenous (i.v.) cisplatin and fluorouracil (5-FU), surgery and postoperative intraperitoneal (i.p.) floxuridine (FUdR) and leucovorin (LV) in patients with locally advanced gastric cancer.
  • T stage downstaging (pretreatment LAP versus surgical pathological stage) was seen in 23% of patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788003.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA56225
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim DH, Kim KM, Park CK: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS; 2009 Aug;117(8):598-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma.
  • There are no known reliable biomarkers which can predict poor clinical outcome following curative resection of gastric adenocarcinoma.
  • Given the importance of signal transducer and activator of transcription 3 (STAT3) activation in carcinogenesis, we attempted to determine whether STAT3 activation is prognostic of survival in curatively resected gastric cancer patients.
  • We analyzed 311 surgically resected gastric cancer specimens for STAT3 activation and its downstream molecules such as matrix metalloproteinase (MMP)-9, MMP-10, cyclin D1, survivin, vascular endothelial growth factor (VEGF)-C, and VEGFR-3 using immunohistochemical studies and assessed their correlation with clinical outcome.
  • The pSTAT3 was detected in 79 (26.1%) of 303 gastric cancers.
  • On multivariate analyses, STAT3 activation was independently associated with inferior DFS (p = 0.049, hazard ratio [HR] = 1.445, 95% CI, 1.025, 2.120) along with AJCC stage IIIA or IIIB (p = 0.004, HR = 1.708, 95% CI, 1.178, 2.475).
  • Based on our data, pSTAT3tyr705 may be a novel prognostic marker for poorer clinical outcome following curative resection and adjuvant therapy in gastric cancer.
  • The clinical impact of a STAT3-targeted agent should be investigated in gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Biomarkers, Tumor / biosynthesis. STAT3 Transcription Factor / biosynthesis. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664131.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Vascular Endothelial Growth Factor C; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3; EC 3.4.24.22 / MMP10 protein, human; EC 3.4.24.22 / Matrix Metalloproteinase 10; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


51. Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC: Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol; 2007 May 1;95(6):461-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
  • BACKGROUND AND OBJECTIVES: The aim of this study was to investigate whether microscopic positive margins are detrimental to the outcome of gastric cancer patients treated with extended (D2/3) gastrectomy.
  • METHODS: Among 2,740 consecutive patients who had undergone extended gastrectomy for advanced gastric cancer between January 1987 and December 2002, 49 patients (1.8%) had positive resection margins on final histology.
  • When both groups of patients were stratified according to nodal stage, a positive resection margin determined a worse prognosis only in patients with node-negative disease (174 months vs. 37 months, P = 0.0001).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17192913.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen; FAM protocol
  •  go-up   go-down


52. Berrisford RG, Veeramootoo D, Parameswaran R, Krishnadas R, Wajed SA: Laparoscopic ischaemic conditioning of the stomach may reduce gastric-conduit morbidity following total minimally invasive oesophagectomy. Eur J Cardiothorac Surg; 2009 Nov;36(5):888-93; discussion 893
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic ischaemic conditioning of the stomach may reduce gastric-conduit morbidity following total minimally invasive oesophagectomy.
  • OBJECTIVE: Oesophagectomy, whether open or minimal access, is associated with a significant incidence of gastric-conduit-related complications.
  • Previous animal and human studies suggest that ischaemic conditioning of the stomach prior to oesophagectomy improves perfusion of the gastric conduit.
  • We have adopted laparoscopic ligation of the left gastric artery 2 weeks prior to minimally invasive oesophagectomy, having identified a relative high incidence of gastric-tube complications through a cumulative summation (CUSUM) analysis.
  • METHODS: This study included 77 consecutive patients who underwent a Total MIO (thoracoscopic oesophageal mobilisation, laparoscopic gastric tube formation, cervical anastomosis).
  • The ligation group comprised 22 consecutive patients, excluding those with middle-third squamous tumours or early-stage adenocarcinoma, who underwent ligation 2 weeks prior to MIO at staging laparoscopy.
  • The effect of ligation of the left gastric artery was followed with a CUSUM analysis.
  • Although gastric mobilisation at MIO was technically more difficult after ligation, there was no significant difference in operating time (ligation, 407 min; control, 425 min) or blood loss (ligation and control, 500 ml).
  • There was less gastric-conduit morbidity in the ligation group (two of 22, 10%; one L, one CN) compared with the control group (11 of 55, 20%; four L, five TN, two CN), but these differences did not reach statistical significance (p=0.211 and p=0.176 Fisher's exact test).
  • The CUSUM analysis showed that during ligation of the left gastric artery, conservatively treated gastric-conduit-related morbidity (leak, resection and re-anastomosis or conduit necrosis) remained within safe limits (10%).
  • There is a trend to reduced morbidity related to gastric-conduit ischaemia, which was demonstrated by a CUSUM analysis.
  • A randomised trial is needed before ligation of the left gastric artery can be routinely recommended.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615914.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Motoshita J, Nakayama H, Taniyama K, Matsusaki K, Yasui W: Molecular characteristics of differentiated-type gastric carcinoma with distinct mucin phenotype: LI-cadherin is associated with intestinal phenotype. Pathol Int; 2006 Apr;56(4):200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics of differentiated-type gastric carcinoma with distinct mucin phenotype: LI-cadherin is associated with intestinal phenotype.
  • Gastric carcinomas (GC) are classified into four phenotypes on the basis of the mucin expression profile: G type (gastric or foveolar phenotype), I type (intestinal phenotype), GI type (intestinal and gastric mixed phenotype) and N type (neither gastric nor intestinal phenotype).
  • Immunohistochemistry was used to examine the expression of epidermal growth factor receptor (EGFR), E-cadherin, liver-intestine (LI)-cadherin, CD44v9 and p53 and correlation of these molecules with mucin phenotype and tumor stage was evaluated.
  • [MeSH-major] Adenocarcinoma / pathology. Cadherins / metabolism. Mucins / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634965.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v9 antigen; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


54. Zhao P, Liu W, Lu YL: Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J Gastroenterol; 2005 Sep 28;11(36):5735-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.
  • AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma.
  • METHODS: FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis.
  • RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa.
  • There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000).
  • The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer.
  • Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
  • [MeSH-major] Acid Anhydride Hydrolases / metabolism. Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237777.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4481500
  •  go-up   go-down


55. Choi JH, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY, Kim IS: Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS; 2006 Sep;114(9):619-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray.
  • However, the role of Stat3 signaling in gastric carcinoma has not yet been fully determined.
  • This study was conducted to investigate the clinical value of phospho-Stat3 expression in gastric carcinoma.
  • Expression of phospho-Stat3 (Tyr705), vascular endothelial growth factor (VEGF), p53, and Bcl-2 was determined by immunohistochemical staining of tissue microarrays from 137 cases of resected gastric cancer specimens.
  • However, there was no significant difference in other clinicopathological parameters, such as tumor stage (T, N, M), pathological type, relapse-free survival, and overall survival between the phospho-Stat3-positive and -negative groups.
  • Co-expression of phospho-Stat3 and VEGF was found in many patients with N3 and Stage IV disease.
  • Further studies are needed to determine the role of phospho-Stat3 in gastric cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. STAT3 Transcription Factor / analysis. Stomach Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948814.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


56. Wang TB, Deng MH, Qiu WS, Dong WG: Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol; 2007 Mar 28;13(12):1794-7; discussion 1797-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer.
  • AIM: To investigate whether serum vascular endothelial growth factor-C (SVEGF-C), VEGF-C, and lymphatic vessel density (LVD) in tumor tissues are related to lymph node metastasis (LNM) and prognosis in gastric cancer.
  • METHODS: SVEGF-C levels of 80 gastric cancer patients and 20 healthy donors were examined using ELISA.
  • RESULTS: The SVEGF-C level in gastric cancer patients (595.9 +/- 201.0 ng/L) was significantly higher (P = 0.000) than controls (360.0 +/- 97.4 ng/L).
  • VEGF-C expression up-regulation was significantly related to differentiation, depth of invasion, LNM, distant metastasis, and pTNM stage (P = 0.000).
  • CONCLUSION: SVEGF-C level, VEGF-C and LVD are related to LNM and poor prognosis of patients with gastric cancer.
  • SVEGF-C may be a biomarker for LNM in gastric cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / secondary. Lymphatic Vessels / pathology. Stomach Neoplasms / blood. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor C / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465468.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC4149954
  •  go-up   go-down


57. Chou NH, Chen HC, Chou NS, Hsu PI, Tseng HH: Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J Gastroenterol; 2006 Nov 28;12(44):7188-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma.
  • AIM: To investigate the clinical and pathological significance of altered retinoblastoma (Rb) encoding protein (pRb) in gastric carcinoma.
  • METHODS: Expression of altered pRb was analyzed in 91 patients with gastric adenocarcinoma by immunohistochemistry.
  • RESULTS: Sixty-five percent (59/91) of the tumors were positively stained and the staining in tumor nuclei of gastric carcinoma ranged 0%-90%.
  • Moreover, strong expression of altered pRb was found in 35% (6/17), 24% (5/21), 17% (8/46) and 0% (0/7) of T1, T2, T3 and T4 gastric carcinomas, respectively.
  • In terms of prognostic significance, univariate analysis showed that poor differentiation [41 (66.1%) vs 34 (42.5%) P = 0.051], advanced tumor stage (P < 0.001) and weakly altered pRb expression [17 (80.5%) vs 58 (49.6%) P=0.044] were associated with worse prognosis in these patients.
  • However, multivariate analysis revealed that advanced tumor stage was the only independent poor prognostic factor (P < 0.001).
  • CONCLUSION: the mutation of Rb gene is frequent in gastric carcinoma.
  • The expression of altered pRb inversely correlates with tumor invasion and is not an independent prognostic marker in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Retinoblastoma Protein / metabolism. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7762-6 [2217208.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):988-93 [2180983.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1138-46 [1659741.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2305-9 [1766677.001]
  • [Cites] Oncogene. 1992 Jan;7(1):101-8 [1741157.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 19;84(16):1251-6 [1640484.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):781-4 [8449603.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):695-9 [8158700.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):161-7 [8026875.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1018-24 [7947078.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1252-7 [7526887.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):442-5 [8621224.001]
  • [Cites] Br J Cancer. 1997;75(1):87-93 [9000603.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3301-12 [9363859.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):604-8 [10567906.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):618-22 [10567909.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):643-6 [2877398.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1394-9 [3823889.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Oncogene. 1989 Jun;4(6):725-9 [2543943.001]
  • [Cites] Oncogene. 1989 Jul;4(7):839-43 [2755701.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1343-6 [1886710.001]
  • (PMID = 17131485.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Other-IDs] NLM/ PMC4087784
  •  go-up   go-down


58. Stephens MR, Blackshaw GR, Lewis WG, Edwards P, Barry JD, Hopper NA, Allison MC: Influence of socio-economic deprivation on outcomes for patients diagnosed with gastric cancer. Scand J Gastroenterol; 2005 Nov;40(11):1351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of socio-economic deprivation on outcomes for patients diagnosed with gastric cancer.
  • OBJECTIVE: Socio-economic deprivation has an influence on the outcome for patients diagnosed with breast, colorectal and bronchial cancer, but there are few data on its association with gastric cancer.
  • The aim of this study was to determine the influence of socio-economic deprivation on outcomes for patients with gastric cancer.
  • MATERIAL AND METHODS: Three hundred and thirty consecutive patients with gastric adenocarcinoma presenting to a single hospital between 1 October 1995 and 30 June 2004 were studied prospectively and deprivation scores calculated using the National Assembly for Wales Indices of Multiple Deprivation.
  • There was no correlation between stage of disease and socio-economic deprivation.
  • These poorer outcomes were not explained by the stage of disease at diagnosis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Cause of Death. Patient Care / standards. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334445.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


59. Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun MH, Fu H: The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol; 2010 Dec;17(12):3354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
  • BACKGROUND: Fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism, located in the FGFR4 gene exon 9, was reported to be associated with malignant tumors prognosis; however, there has been no relevant research for gastric cancer.
  • The purpose of this study was to investigate the clinical significance of FGFR4 Gly388Arg polymorphism as well as the mRNA expression of FGFR4 in patients with gastric cancer.
  • METHODS: The mRNA expression of FGFR4 in 103 gastric cancer tissues and corresponding normal tissues were measured by reverse transcription polymerase chain reaction (PCR) and real-time quantitative PCR.
  • PCR-restriction fragment length polymorphism analysis was performed to detect the FGFR4 Gly388Arg in 103 gastric cancer tissues.
  • FGFR4 expressions in mRNA levels were higher in gastric cancer tissues compared with those in relevant normal tissues.
  • Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054-4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658-7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on this study, FGFR4 Arg388 genotype-a marker for gastric cancer progression-may predict prognosis of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Carcinoma, Signet Ring Cell / genetics. Gastric Mucosa / pathology. Polymorphism, Genetic / genetics. Receptor, Fibroblast Growth Factor, Type 4 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20844967.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4
  •  go-up   go-down


60. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, Noh SH: Advanced gastric carcinoma with signet ring cell histology. Oncology; 2007;72(1-2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced gastric carcinoma with signet ring cell histology.
  • BACKGROUND: Gastric signet ring cell carcinoma (SRC) is a histological type based on microscopic characteristics and not on biological behavior.
  • This study compared the clinicopathological features and prognosis of advanced SRC with non-signet ring cell adenocarcinoma (NSRC) of the stomach.
  • METHODS: We reviewed the records of 4,759 consecutive patients diagnosed with advanced gastric adenocarcinoma who were resected surgically from 1987 to 2003.
  • RESULTS: Significant differences were noted in tumor size, Borrmann type, depth of invasion, lymph node metastasis, peritoneal dissemination and TNM stage.
  • CONCLUSIONS: Advanced gastric SRC tends toward deeper tumor invasion and more lymph node and peritoneal metastasis than NSRC.
  • Advanced gastric SRC had a worse prognosis than NSRC.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology


61. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • P53 expression was detected in 42.9% (15 of 35) of gastric cancer tissues of the patients.
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Asoglu O, Karanlik H, Parlak M, Kecer M, Muslumanoglu M, Igci A, Ozmen V, Gulluoglu M, Kapran Y: Metastatic lymph node ratio is an independent prognostic factor in gastric cancer. Hepatogastroenterology; 2009 May-Jun;56(91-92):908-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is an independent prognostic factor in gastric cancer.
  • BACKGROUND/AIMS: The metastatic status of the regional lymph node is the most significant prognostic factor for gastric cancer.
  • The aim of this study is to evaluate the prognostic significance of the ratio of metastatic to examined lymph nodes (N ratio) for identifying a high-risk subgroup of patients with gastric cancer.
  • METHODOLOGY: The postoperative survival of 264 consecutive patients with operable gastric cancer was analyzed with regard to its N ratio and current N classification.
  • Cox regression analysis revealed that N ratio was sensitive prognostic factor in these surgically treated patients, which were also significantly correlated with extent of lymph node dissection and pathologic tumor stage (p<0.05).
  • CONCLUSIONS: N ratio can be recommended as an applicable parameter for lymph node involvement of gastric cancer.
  • It is a more effective and precise indicator for prognostic stratification of patients with lymph node positive gastric cancer than the current N classification of the tumor-node-metastasis system.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621727.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


63. Dumot JA, Vargo JJ 2nd, Falk GW, Frey L, Lopez R, Rice TW: An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc; 2009 Oct;70(4):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASUREMENTS: Histologic response was defined by the worst pathology obtained at any level of the esophagus or gastric cardia in 1 of 3 categories:.
  • Twenty-seven of 30 patients (90%) had downgrading of pathology stage after treatment.
  • During follow-up, 3 of 6 patients with complete response had recurrence of dysplasia or cancer in the gastric cardia.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Carcinoma, Squamous Cell / therapy. Cryosurgery / methods. Esophageal Neoplasms / therapy


64. Huang Q, Huang Q, Lin W, Lin J, Lin X: Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis. J Cancer Res Clin Oncol; 2010 Aug;136(8):1275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
  • PURPOSE: This study aimed to investigate the expression level of human proteasome activator PA28beta subunit (PA28beta) in gastric adenocarcinomas (GA) tissues and investigate its potential role in GA carcinogenesis.
  • Decreased expression was dependent on histological type, TNM stage, and differentiation grade.
  • [MeSH-major] Adenocarcinoma / genetics. Muscle Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Mol Cancer Res. 2008 Mar;6(3):426-34 [18337449.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2480-9 [17363565.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1693-704 [15789341.001]
  • [Cites] Biochem J. 2000 Jan 1;345 Pt 1:1-15 [10600633.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;268:73-89 [12083009.001]
  • [Cites] Trends Cell Biol. 2005 Jan;15(1):27-33 [15653075.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(13):1596-600 [15224184.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7803-10 [11691796.001]
  • [Cites] BMC Cancer. 2009 Nov 04;9:391 [19889225.001]
  • [Cites] Mol Cancer Ther. 2005 Aug;4(8):1157-66 [16093431.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1219-27 [18446369.001]
  • [Cites] Exp Mol Med. 2008 Dec 31;40(6):709-20 [19116456.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6221-30 [11012676.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):494-501 [18223224.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5936-42 [10557080.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):3959-62 [8033121.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2092-101 [16893879.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2546-57 [16331256.001]
  • [Cites] Ann Rheum Dis. 2006 Aug;65(8):1021-7 [16414974.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7815-22 [15944286.001]
  • [Cites] Arch Biochem Biophys. 2000 Dec 1;384(1):174-80 [11147828.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):98-103 [14661019.001]
  • [Cites] Discov Med. 2009 Jun;8(40):23-7 [19772838.001]
  • [Cites] Mol Cancer. 2006 Nov 24;5:64 [17123452.001]
  • [Cites] Mol Biol Rep. 1999 Apr;26(1-2):11-4 [10363640.001]
  • [Cites] EMBO J. 2001 Nov 1;20(21):5898-907 [11689430.001]
  • (PMID = 20140627.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Muscle Proteins; EC 3.4.25.1 / PSME2 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


65. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D: Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract; 2005 Jan;59(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.
  • It may play an important role in gastric tumorigenesis.
  • Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.
  • The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).
  • There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).
  • Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707466.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins
  •  go-up   go-down


66. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • Methylation frequencies of stage III and IV tumor tissues was significantly higher than that in stage I and II tumor tissues (P = 0.01).
  • Positive immunostaining of stage III and IV tumor tissues was significantly lower than stage I and II tumor tissues (P<0.01).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


67. Smith BR, Stabile BE: Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy. J Gastrointest Surg; 2007 Feb;11(2):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy.
  • National trends indicate a longstanding decline in gastric adenocarcinoma due presumably to a decreasing prevalence of Helicobacter pylori infection.
  • Nonetheless, surgical outcomes continue to include relatively high morbidity and mortality rates owing to the advanced stage of disease encountered.
  • We hypothesize that recent immigration patterns are responsible for a leveling off or even reversal of the declining incidence of gastric cancer associated with H. pylori infection.
  • A retrospective review of a consecutive case series at a public teaching hospital located in an area of high immigration was conducted that included all patients presenting, from 1995 through 2004, with gastric adenocarcinoma.
  • There was no decline in the frequency of gastric adenocarcinoma among the study population over the 10 years.
  • The operation rate decreased and the gastric resection rate increased from the early period to the recent period as fewer incurable advanced stage (M1) patients underwent exploratory laparotomy and were palliated by nonoperative means.
  • We conclude that in an area of high immigration there has been no decline in gastric adenocarcinoma rates over the past decade, and the marked reduction in perioperative mortality was due to near elimination of nontherapeutic laparotomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparotomy / mortality. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6220-32 [16135489.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):708-12 [2458160.001]
  • [Cites] Gut. 2005 Nov;54(11):1541-5 [15955787.001]
  • [Cites] Am Surg. 2005 Sep;71(9):797-801 [16468522.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):7-13 [3337564.001]
  • [Cites] Curr Probl Surg. 2005 Dec;42(12):796-862 [16344044.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S30-6 [7762737.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):347-51 [8658218.001]
  • [Cites] Curr Probl Surg. 2005 Nov;42(11):756-89 [16310017.001]
  • [Cites] Gastrointest Endosc. 1994 Nov-Dec;40(6):694-9 [7859967.001]
  • [Cites] Endoscopy. 1992 Jun;24(5):424-7 [1505491.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4509-17 [16002841.001]
  • [Cites] Surgery. 1993 Jan;113(1):14-27 [8417483.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12 ):1153-8 [9373284.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):1016-9 [11443448.001]
  • [Cites] Epidemiol Rev. 1986;8:1-27 [3533579.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):336-46 [8658217.001]
  • [Cites] Pediatrics. 2001 Feb;107(2):373-80 [11158472.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 17390160.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Mühlmann G, Untergasser G, Zitt M, Zitt M, Maier H, Mikuz G, Kronberger IE, Haffner MC, Gunsilius E, Ofner D: Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Arch; 2010 Jun;456(6):635-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer.
  • Here, we investigated the expression of Dkk-3 protein in gastric cancer and its potential value as a prognostic marker.
  • Dkk-3 expression was analyzed by immunohistochemistry in 136 tumor samples and was correlated with microvessel density (MVD), tumor stage, and grading as well as the clinical outcome of the patients.
  • In tumor cells, overexpression of Dkk-3 was found in 41 (30.1%) of all cases and was correlated significantly to pT-stage (p < 0.05) and UICC stage (p < 0.05).
  • Dkk-3 expression in tumor vessels of patients with gastric cancer identifies a population of patients with relatively favorable prognosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Intercellular Signaling Peptides and Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):5027-36 [16568085.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):117-21 [11408931.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1539-47 [18033687.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Surg Oncol. 1997 Aug;65(4):232-6 [9274786.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Oncogene. 2006 Oct 19;25(49):6528-37 [16751809.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):9-28 [12832961.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2234-6 [12805321.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Gene. 2002 Jan 9;282(1-2):151-8 [11814687.001]
  • [Cites] J Urol. 2004 Mar;171(3):1314-8 [14767340.001]
  • [Cites] Gene. 1999 Oct 1;238(2):301-13 [10570958.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 5;268(1):20-4 [10652205.001]
  • [Cites] Cancer Sci. 2009 Aug;100(8):1414-20 [19493271.001]
  • [Cites] Dis Markers. 2008;24(2):101-9 [18219095.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):707-13 [15226763.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):49-60 [19051296.001]
  • [Cites] Gene. 2003 Jan 2;302(1-2):179-83 [12527209.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3442-55 [19633687.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 20473620.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK3 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


69. David S, Kan T, Cheng Y, Agarwal R, Jin Z, Mori Y: Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer. Biochem Biophys Res Commun; 2009 Jan 16;378(3):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer.
  • Tachykinin-1 (TAC1) is the precursor protein for neuroendocrine peptides, including substance P, and is centrally involved in gastric secretion, motility, mucosal immunity, and cell proliferation.
  • Here we report aberrant silencing of TAC1 in gastric cancer (GC) by promoter hypermethylation.
  • TAC1 methylation and mRNA expression in 47 primary GCs and 41 noncancerous gastric mucosae (NLs) were analyzed by utilizing real-time quantitative PCR-based assays.
  • There was no significant association between TAC1 methylation and age, gender, stage, histological differentiation, or the presence of Helicobacter pylori.
  • Further studies are indicated to elucidate the functional involvement of TAC1 in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing. Protein Precursors / genetics. Stomach Neoplasms / genetics. Tachykinins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046942.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Precursors; 0 / Tachykinins; 0 / protachykinin
  •  go-up   go-down


70. Fang WL, Wu CW, Lo SS, Chen JH, Hsieh MC, Shen KH, Li AF, Tai LC, Lui WY: Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):1227-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma.
  • BACKGROUND/AIMS: Signet ring cell carcinoma and mucinous carcinoma are mucin-producing gastric cancers.
  • METHODOLOGY: From December 1987 to July 2005, a total of 1612 gastric cancer patients received curative surgery, 128 patients with signet ring cell carcinoma and 48 with mucinous carcinoma were enrolled in this study.
  • RESULTS: Early stage (stage I and II) patients with mucinous carcinoma were associated with more male predominant (p = 0.002), larger tumor size (p = 0.020), deeper cancer invasion (p < 0.001), and a worse 5-year overall survival (63.6% vs 88.2%, p = 0.012) than those with signet ring cell carcinoma.
  • There was no significant difference between the two groups with advanced stage in 5-year overall survival.
  • CONCLUSIONS: Patients with mucinous carcinoma had different biological behaviors with those with signet ring cell carcinoma, in particular early stage, hence had a worse survival.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760976.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


71. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • Methylation frequencies of stage III and IV tumor tissues were significantly higher than that in stage I and II tumor tissues (p <.05).
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


72. Gasparini G, Inelmen EM, Enzi G, Santoro C, Sergi G, Cardin F, Terranova O: Clinical and prognostic aspects of gastric carcinoma in the elderly. J Gastrointest Surg; 2006 Mar;10(3):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and prognostic aspects of gastric carcinoma in the elderly.
  • The aim of the present study was to analyze the influence of various factors on the prognosis for elderly patients with gastric carcinoma.
  • They all had a histologically confirmed diagnosis of gastric adenocarcinoma.
  • On univariate analysis, significant prognostic factors in the two age groups were gender, stage, histotype (Lauren's intestinal type), Charlson index, and type of surgery (curative resection, palliative resection, and no surgery).
  • On multivariate analysis, independent prognostic factors were the Charlson index, tumor stage, and age group.
  • The 17-month survival rate was 55.6% for surgically treated patients and 0% for the untreated cases in stage 4 (P = 0.03).
  • Gastric cancer should be treated with conventional surgery even in the very elderly, since the survival rate for this age group does not differ significantly from the figures for younger patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):520-5 [10947021.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1 Suppl 1):S51-2 [11989924.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):254-7 [10779055.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S31-4 [12914387.001]
  • [Cites] World J Surg. 2000 Apr;24(4):465-72 [10706921.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):183-9; discussion 194-6, 199 [11866135.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S35-8 [12914388.001]
  • [Cites] World J Surg. 1984 Jun;8(3):315-20 [6464488.001]
  • [Cites] Age Ageing. 2003 Sep;32(5):484-6 [12957994.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):451-3 [11504514.001]
  • [Cites] J Am Geriatr Soc. 1997 Apr;45(4):482-8 [9100719.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):29-34 [12080223.001]
  • [Cites] Minerva Chir. 2004 Oct;59(5):479-87 [15494675.001]
  • [Cites] Gastric Cancer. 2004;7(3):154-9 [15449203.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 15;89(20):1489-97 [9337345.001]
  • [Cites] Am Surg. 1987 Mar;53(3):170-3 [3826909.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):235-8 [15615661.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81 [15588798.001]
  • (PMID = 16504885.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Caruso RA, Napoli P, Nania A, Parisi A, Fedele F, Zuccalà V: Mitochondrion-rich differentiated adenocarcinomas of the stomach: clinicopathological, immunohistochemical and electron microscopy study of nine cases. Virchows Arch; 2010 May;456(5):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic and prognostic data of nine patients with mitochondrion-rich carcinomas (MRC) were compared retrospectively to data of 101 patients with conventional gastric adenocarcinomas.
  • MRC was defined as a tumour composed predominantly, or entirely, of columnar adenocarcinoma cells with eosinophilic cytoplasm and a strong supranuclear immunoreactivity for antimitochondrial antibody.
  • MRC showed immunohistochemical findings compatible with gastric differentiation (CK7+/CK20-/CDX-) When MRC were compared with non-MRC carcinomas, tumour size (< 4 cm vs >4 cm, P < 0.01) , frequency of lymph node metastases (11% vs. 80%, P < 0.01), low stage (I, II) at diagnosis (100% vs. 56%, P < 0.01), Goseki's group I (100% vs. 6%, P < 0.01), and better survival (0% vs. 70%, P < 0.01) differed significantly.
  • [MeSH-major] Adenocarcinoma / pathology. Mitochondria / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2009 Dec;55(6):665-82 [20002768.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1382-8 [17063077.001]
  • [Cites] Science. 1956 Aug 10;124(3215):269-70 [13351639.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):447-9 [18387987.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Pathol Res Pract. 2007;203(7):539-41 [17590281.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Hum Pathol. 2009 Apr;40(4):478-83 [19144383.001]
  • [Cites] Anat Rec. 1993 Jun;236(2):259-79 [8338232.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Virchows Arch. 2009 May;454(5):481-95 [19343360.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Arch Pathol Lab Med. 2000 Oct;124(10 ):1547-52 [11035596.001]
  • [Cites] Histopathology. 2007 Nov;51(5):725-7 [17927604.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):116-23 [14720143.001]
  • [Cites] Front Biosci (Landmark Ed). 2010 Jan 01;15:595-603 [20036835.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] Gut. 1992 May;33(5):606-12 [1377153.001]
  • [Cites] Cell Death Differ. 2009 Jan;16(1):3-11 [18846107.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Hum Pathol. 2004 May;35(5):576-81 [15138932.001]
  • (PMID = 20393747.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


74. Ishii HH, Gobe GC, Ebihara Y: p53 is an indicator of tumor progression in early but not advanced gastric carcinomas. Hepatogastroenterology; 2007 Oct-Nov;54(79):2159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 is an indicator of tumor progression in early but not advanced gastric carcinomas.
  • BACKGROUND/AIMS: p53 plays an important role in the development of gastric carcinomas through its effect on apoptosis.
  • This project assessed its value in early and advanced stage gastric carcinomas.
  • METHODOLOGY: The characteristics of positive staining for p53 was evaluated in 202 gastric adenocarcinomas classified into early stage (T1) (127 cases) and advanced stage (T2, 3 and 4) (75 cases) using the tumor-node-metastasis classification.
  • RESULTS: The mucosa of early stage and both mucosa and subserosa of advanced cancers were examined. p53-positive early stage cancers had more apoptosis but also more proliferation than p53-negatives (P<0.05), perhaps indicating conferral of a growth advantage.
  • CONCLUSIONS: p53 may be useful as an indicator of development and progression in early stage gastric cancers but this is not the case for advanced stage gastric cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Apoptosis / physiology. Cell Proliferation. Disease Progression. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251181.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although the incidence of adenocarcinoma of the stomach has decreased over the past several decades, gastric cardia carcinoma has increased over the same period.
  • RESULTS: In the clinicopathologic analysis, patients who had cardia carcinoma tended to have tumors with poorly differentiated histology according to the World Health Organization classification system (P = 0.012), diffuse type according to the Lauren classification system (P = 0.049), and advanced pathologic TNM stage (P < 0.001).
  • In the multivariate analysis, tumor location in the cardia was confirmed as an independent, poor prognostic factor in patients with gastric carcinoma.
  • The current results support the hypothesis that cardia carcinoma forms a specific category of gastric carcinoma that is distinct from noncardia carcinoma.


76. Joo M, Kim H, Kim MK, Yu HJ, Kim JP: Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol; 2005 Jul;20(7):1039-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma.
  • However, the expression and distribution of Ep-CAM in gastric premalignant and malignant lesions are not well known.
  • METHOD: We examined the expression of Ep-CAM in 99 cases of gastric adenocarcinoma and associated uninvolved gastric mucosa, 39 cases of gastric biopsy specimens with chronic gastritis (CG) with or without intestinal metaplasia (IM) (25 cases) and gastric epithelial dysplasia (GED) (14 cases) by immunohistochemical staining.
  • In gastric adenocarcinoma, we correlated the results with established prognostic factors, and in IM and GED, with Hepatocyte paraffin 1 (Hep Par 1) expression, introduced as a marker of IM.
  • RESULTS: Ep-CAM overexpression was noted in 0% of normal epithelia, 93.9% of IM, 42.9% of GED and 34.3% of adenocarcinoma.
  • The average immunostaining score of normal epithelia, IM, GED and gastric adenocarcinoma was 0.14 (+/- 0.26), 7.18 (+/- 1.93), 5.67 (+/- 2.29) and 4.09 (+/- 1.89), respectively.
  • Ep-CAM overexpression in adenocarcinoma correlated with Lauren classification and histologic grade, but not with tumor stage, lymph node metastasis and p53 expression.
  • CONCLUSION: Our findings suggest that increased levels of Ep-CAM represent an early event in gastric carcinogenesis, and seem to have a specific relation with the development of IM as a morphoregulatory molecule.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Gastric Mucosa / metabolism. Intestines / pathology. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955212.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  •  go-up   go-down


77. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, Pop F, Radu H, Al-Hajaar N, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocan T: [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Mar-Apr;103(2):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Aspecte clinice cu implicaţie prognostică în cancerul gastric--analiză a 468 cazuri de adenocarcinom gastric.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which were operated in the 3rd Surgical Clinic--Cluj Napoca--01.01.1998-31.12.2003.
  • Patients in pTNM 0 stage were significantly younger than the rest of patients, with an average of 7.5 years.
  • The male/female ratio was 1.7:1, this ratio being significantly higher in cases with proximal gastric cancers.
  • There was not found any significant correlation between the interval : onset of symptoms and surgery, and pTNM stage.
  • This significant group of patients studied has maintained characteristics encountered in populations with higher incidence of gastric adenocarcinoma, men being more frequently affected, distal localization and intestinal histologic type being encountered more frequently.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457096.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


78. Lee DY, Park CS, Kim HS, Kim JY, Kim YC, Lee S: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications.
  • OBJECTIVES: To investigate the role of maspin and p53 expression in the progression of gastric cancer, and its value as a prognostic indicator.
  • MATERIALS AND METHODS: The expression of maspin and p53 in 152 cases of gastric cancer was detected by immunohistochemistry and compared with the clinicopathologic tumor parameters.
  • The relationship between maspin and p53 expression was also analyzed in the gastric cancers.
  • Two patterns of immunostaining for maspin were seen in the maspin-positive gastric cancer cases: cytoplasm-only staining (67.0%, 73 of 109 cases) and staining of both cytoplasm and nucleus (33.0%, 36 of 109 cases).
  • Maspin expression showed a negative association with histologic grade, depth of invasion, metastasis, and TNM stage (all P<0.05).
  • p53 expression showed an association with node metastasis, and TNM stage (both P<0.05).
  • In univariate log-rank analysis, loss of maspin expression, histologic grade, distant metastasis, and TNM stage were associated with patient survival.
  • However, in multivariate analysis TNM stage and regional node metastasis were the only independent prognostic factors.
  • Maspin expression is inversely correlated with mutant p53 expression in gastric cancer, which suggests that maspin expression is regulated by the p53 pathway.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091326.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


79. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Peschos D, Vezyraki P, Kalfakakou V, Metsios A, Charalampopoulos A, Macheras A, Agnantis N, Evangelou A: Serum and tissue selenium levels in gastric cancer patients and correlation with CEA. Anticancer Res; 2009 Aug;29(8):3465-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and tissue selenium levels in gastric cancer patients and correlation with CEA.
  • MATERIALS AND METHODS: In eighty patients who had been operated on for primary gastric cancer, serum Se and carcinoembryonic antigen (CEA) levels were measured preoperatively using a fluorometric and immunoradiometric assay (IRMA), respectively.
  • The serum CEA was 12+/-1.9 U ml(-1) in the gastric cancer patients and 2.1 U ml(-1) in the control group (p<0.001).
  • There was no correlation between serum/tissue Se concentration and disease stage/histological type or gender in the patient group.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Intestinal Neoplasms / metabolism. Selenium / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661375.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; H6241UJ22B / Selenium
  •  go-up   go-down


80. Anagnostopoulos GK, Stefanou D, Arkoumani E, Chalkley L, Karagiannis J, Paraskeva K, Mathou N, Dellaporta E, Tsianos E, Agnantis NJ: Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg; 2007 Jul-Sep;70(3):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study.
  • Our aim was to immunohistochemically study Bax protein expression in gastric carcinomas and correlate its expression with clinicopathological parameters and prognosis.
  • PATIENTS AND METHODS: Immunohistochemistry was performed, using a monoclonal antibody against bax, in paraffin-embedded tumor specimens from 47 cases of gastric cancer.
  • Univariate analysis showed that the variables with a significant negative impact on survival were: high TNM tumour stage, depth of penetration in the gastric wall, lymph node involvement, and Bax protein expression.
  • CONCLUSION: Negative Bax expression in gastric cancer is associated with de-differentiation, lymph node metastases, and poor clinical prognosis.
  • Bax protein expression might play an important role in the development and phenotypic differentiation of gastric carcinomas and tumor progression.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. bcl-2-Associated X Protein / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal. Carcinoma / pathology. Carcinoma / secondary. Cell Differentiation / genetics. Coloring Agents. Disease Progression. Female. Gastric Mucosa / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074738.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BAX protein, human; 0 / Coloring Agents; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


81. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P=0.0402 and 51.5 vs 84.6%, P=0.0247, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


82. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E: Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol; 2006 Jan;30(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases.
  • Recently, we showed that Epstein-Barr virus (EBV)-positive gastric carcinoma (GC) forms a distinct clinicopathologic entity with a better prognosis due to lower incidence of lymph node metastases (LN+).
  • Twenty EBV-positive primary tumors (PT) (9 LN+) were matched with 28 EBV-negative GC (11 LN+) for T- and N-stage, gender, and age.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / virology. Lymphatic Metastasis / immunology. Stomach Neoplasms / pathology. T-Lymphocytes, Cytotoxic / immunology. Tumor Virus Infections / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330943.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • The prognosis is poor, since detection is usually at a late stage and metastatic spread occurs early.
  • In addition, 40 gastric cardia cancers were investigated to compare the pattern of imbalance at these loci.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In gastric cardia cancers, loss ranged from 12% to 27% (of informative cases), being most frequent at marker D7S3037.
  • The difference between oesophageal and gastric adenocarcinomas was highest for polymorphic marker D7S483 (p=0.05).
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


84. Qiu MZ, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, Aziz F, Wang DY, Xu RH: Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. J Transl Med; 2010;8:107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma.
  • BACKGROUND: The existence of circulating tumor cells (CTCs) in peripheral blood as an indicator of tumor recurrence has not been clearly established, particularly for gastric cancer patients.
  • We conducted a retrospective analysis of the relationship between CTCs in peripheral blood at initial diagnosis and clinicopathologic findings in patients with gastric carcinoma.
  • METHODS: Blood samples were obtained from 123 gastric carcinoma patients at initial diagnosis. mRNA was extracted and amplified for carcinoembryonic antigen (CEA) mRNA detection using real-time RT-PCR.
  • CEA mRNA expression significantly correlated with T stage and postoperative recurrence status (P = 0.001).
  • CONCLUSIONS: CEA mRNA copy number in peripheral blood at initial diagnosis was significantly associated with disease recurrence in gastric adenocarcinoma patients.
  • Real-time RT-PCR detection of CEA mRNA levels at initial diagnosis appears to be a promising predictor for disease recurrence in gastric adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / genetics. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):128-32 [9440733.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3106-10 [9242433.001]
  • [Cites] Surg Today. 1998;28(7):701-6 [9697262.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1368-72 [9823981.001]
  • [Cites] Surg Today. 2005;35(6):436-41 [15912289.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):248-56 [16320073.001]
  • [Cites] Trends Mol Med. 2006 Mar;12(3):130-9 [16488189.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5972-7 [17062668.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):205-9 [17936797.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):153-9 [19050704.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1432-9 [10735890.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):918-24 [11011120.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):85-9 [11146784.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):189-94 [11176124.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1647-53 [11410502.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):17-20 [11438448.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1351-61 [11598148.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):548-53 [11802221.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):195-203 [12065095.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2073-84 [12114406.001]
  • [Cites] Int J Mol Med. 2003 Feb;11(2):217-21 [12525881.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1091-4 [12671691.001]
  • [Cites] Trends Mol Med. 2003 May;9(5):189-95 [12763523.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):88-95 [12766613.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):219-27 [14639606.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):531-7 [14760074.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Clin Oncol. 1984 Dec;10(4):325-32 [6210169.001]
  • [Cites] Eur J Cancer. 1991;27(11):1461-5 [1720636.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):725-9 [7512130.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):166-9 [9008229.001]
  • [Cites] Gut. 1996 Nov;39(5):717-21 [9014772.001]
  • [Cites] Gut. 1997 Apr;40(4):512-5 [9176080.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):64-8 [9660027.001]
  • (PMID = 21040522.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / DNA Primers; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2989934
  •  go-up   go-down


85. Park JM, Kim JH, Park SS, Kim SJ, Mok YJ, Kim CS: Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II. World J Surg; 2008 Jun;32(6):1037-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II.
  • BACKGROUND: According to the fifth edition of the UICC TNM classification, stage II gastric cancer has three subgroups: T1N2M0, T2N1M0, and T3N0M0.
  • This study was designed to investigate the prognosis of stage II gastric cancer according to the T and N category to verify the accuracy of TNM staging for stage II and to determine the prognostic factors for patients with stage II gastric cancer by subgroup.
  • METHODS: Clinicopathologic data from 326 patients with stage II gastric cancer were studied.
  • Univariate survival analysis showed that age, gender, histological type, and the extent of lymph node dissection were significant prognostic factors for stage II gastric cancer.
  • Thus, our data support the accuracy of the TNM staging classification for stage II gastric cancer.
  • However, before recommending limited lymph node dissection for T2N1 stage disease, development of a preoperative method for prediction of depth of invasion and lymph node status is needed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lymph Node Excision. Neoplasm Staging. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2008 Sep;32(9):2127-8 [18563483.001]
  • [Cites] World J Surg. 1999 May;23(5):492-7; discussion 497-8 [10085399.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):173-178 [11957092.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1674-80 [11527695.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):252-9 [11922742.001]
  • [Cites] Surgery. 2000 Feb;127(2):129-35 [10686976.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):25-37 [11192920.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):16-20 [16788938.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1303-9 [8869090.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):334-6 [2021850.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1763-5 [10760749.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):559-62 [16446988.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7508-11 [16437724.001]
  • [Cites] World J Surg. 1993 May-Jun;17(3):410-4; discussion 415 [8337889.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • (PMID = 18347851.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Ye ZB, Ma T, Li H, Jin XL, Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1747-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma.
  • AIM: To explore the effect of intratumoral expressions of interleukin-12 (IL-12) and interleukin-18 (IL-18) on clinical features, angiogenesis and prognosis of gastric carcinoma.
  • METHODS: The expressions of IL-12 and IL-18 from 50 samples of gastric cancer tissue were analyzed by immunohistochemistry, and microvessel density (MVD) was determined with microscopic imaging analysis system.
  • IL-12 was significantly associated with pathologic differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage, and IL-18 was closely related to distant metastasis.
  • The multivariate analysis with Cox proportional hazard model revealed IL-12, MVD and T stage were independent prognostic factors.
  • CONCLUSION: The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / metabolism. Interleukin-12 / metabolism. Interleukin-18 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1999 Dec;13(15):2195-202 [10593867.001]
  • [Cites] Int J Urol. 2004 Aug;11(8):647-52 [15285756.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):126-9 [11471895.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Aug;26(4):302-6 [11559342.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2050-5 [11596019.001]
  • [Cites] Auris Nasus Larynx. 2004 Sep;31(3):239-45 [15364358.001]
  • [Cites] In Vivo. 1993 May-Jun;7(3):265-9 [8357968.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):38-43 [8847724.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):817-24 [9120387.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5070-7 [10227975.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43 [16060834.001]
  • [Cites] Cytokine. 2002 Aug 7;19(3):126-37 [12242079.001]
  • [Cites] FASEB J. 2003 Apr;17(6):728-30 [12594171.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):91-5 [14630085.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 [10639148.001]
  • (PMID = 17461482.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4146958
  •  go-up   go-down


87. Mizoshita T, Tsukamoto T, Tanaka H, Takenaka Y, Kato S, Cao X, Joh T, Tatematsu M: Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings. Pathol Int; 2005 Oct;55(10):611-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings.
  • The clinicopathological significance of colonic and small-intestinal phenotypes has hitherto remained unclear in gastric cancers.
  • The purpose of the present study was therefore to examine 86 gastric carcinomas histologically and phenotypically using several phenotypic markers, including colon-specific carbonic anhydrase 1 (CA1) and sucrase as small-intestine specific marker.
  • Of 86 gastric cancers, sucrase and CA1 expression was observed in 12 (14.0%) and only in two cases (2.3%), respectively, associated with other intestinal markers such as villin and mucin core protein (MUC)2.
  • In the sucrase cases, expression appeared independent of the stage.
  • No association was observed between colonic and small-intestinal phenotypes, and lymph node metastasis and postoperative survival in the advanced gastric cancer cases with intestinal phenotypic expression.
  • In conclusion, the data suggest that colonic phenotype occurs rarely in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colon / metabolism. Intestine, Small / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185290.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; EC 3.2.1.48 / Sucrase; EC 4.2.1.- / Carbonic Anhydrase I
  •  go-up   go-down


88. Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U: Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol; 2007 Mar;16(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
  • To explore the relevance of XIAP, Smac/DIABLO, and XAF1 for carcinogenesis and tumor progression, we analyzed 46 primary gastric adenocarcinomas and non-neoplastic gastric mucosa samples by quantitative real-time polymerase chain reaction.
  • XIAP, Smac/DIABLO, and XAF1 expression was found in all non-neoplastic gastric mucosa samples and all adenocarcinomas.
  • XIAP expression levels did not change between non-neoplastic gastric mucosa and adenocarcinomas or between carcinomas of early and advanced stages.
  • Importantly, the ratio of XIAP to XAF1 expression significantly (P=0.03) increased from non-neoplastic mucosa to adenocarcinomas and the increase was even higher in carcinomas of advanced stage (P=0.01).
  • In conclusion, an increased expression ratio of XIAP to XAF1 in combination with a disturbed expression of the XAF1 splice variants could be shown in gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis. Apoptosis Regulatory Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Alternative Splicing. Gastric Mucosa / metabolism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / genetics. Mitochondrial Proteins / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism. Up-Regulation. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471152.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XAF1 protein, human; 0 / XIAP protein, human
  •  go-up   go-down


89. Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol; 2010 Jan;17(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
  • BACKGROUND: The present study investigated the clinical significance of S100 calcium binding protein A4 in the development, progression, and metastasis of gastric cancer.
  • METHODS: Tumor tissue, adjacent normal tissue, and lymph node and peritoneal metastases were obtained from patients with gastric cancer, and their gene expression profiles were analyzed by Affymetrix GeneChip HG-U133A2.0 array.
  • The expression of S100A4 was detected by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) in gastric tumor tissue and lymph node and peritoneum metastasis.
  • Immunohistochemistry was employed to analyze S100A4 expression in 436 clinicopathologically characterized gastric cancer cases and in corresponding distant metastases from 61 patients.
  • The expression of S100A4 in lymph node and peritoneal metastases was significantly higher than that in gastric tumor tissue.
  • The expression of S100A4 messenger RNA (mRNA) or protein differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph node and peritoneal metastases.
  • Further multivariate analysis suggested that depth of invasion, lymph node and distant metastases, tumor-node-metastasis (TNM) stage, and upregulation of S100A4 were independent prognostic indicators for the disease.
  • Expression of S100A4 in gastric cancer is associated significantly with lymph node and distant metastases, and poor prognosis.
  • S100A4 may be a useful marker to predict development, progression, and metastasis of gastric cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastric Mucosa / metabolism. S100 Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Gastrectomy. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820999.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


90. Choi JH, Kim YB, Lim HY, Park JS, Kim HC, Cho YK, Han SW, Kim MW, Joo HJ: 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology; 2007 Jan-Feb;54(73):290-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
  • BACKGROUND/AIMS: Although adjuvant chemotherapy has demonstrated small but significant survival benefit in locally advanced gastric cancer in several meta-analyses, optimal chemotherapy regimen remains to be determined.
  • METHODOLOGY: We retrospectively analyzed the survival of 207 gastric cancer patients (stage IB: 19, II: 65, IIIA: 58, IIIB: 28, IV: 37) who underwent 5-fluorouracil (5-FU), mitomycin-C (MMC), and polysaccharide-K (PSK) chemoimmunotherapy (CITX) after curative resection (FM group).
  • The survival of FM group was compared with that of historical control cohort of 103 patients with almost identical stage distribution who received 5-FU and doxorubicin-based chemotherapy (FA group).
  • FM group showed superior 5-year OS (84.4% vs. 67.6%, p = 0.019) compared with FA group in stage IB or II patients without significant difference (p = 0.222) in stage IIIA to IV.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Mitomycin / administration & dosage. Peripheral Nerves / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419278.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


91. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U, Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res; 2007 Jul-Aug;27(4A):1975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
  • BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas.
  • Additionally, MUC1 and TF were down-regulated in stage III/IV tumors, while a higher binding of gal-1 was observed in stage III/IV tumors, suggesting a substantial role of this antigen in endometrial carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649808.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


92. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata S, Yamamoto H, Kim BS, Matsuki N, Sawa T, Noh SH, East Asia Surgical Oncology Group: Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology; 2007 Mar;54(74):634-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy.
  • BACKGROUND/AIMS: Lymph node dissection is an essential component of curative resection for advanced gastric cancer.
  • METHODOLOGY: Patients enrolled in the study had potentially curable gastric adenocarcinoma in an advanced stage, T2, T3 or T4/N1 or N2.
  • The stage migration by D4 was found in 10 (7.5%).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523339.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Greece
  •  go-up   go-down


93. Lee SY, Hwang I, Park YS, Gardner J, Ro JY: Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol; 2010 Jun;36(6):1461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes?
  • Gastric carcinoma is the most common cancer and the second most common cause of cancer-related death in Korea.
  • Among the category I prognostic factors of gastric carcinoma, lymph node metastasis (nodal status) is considered to be the strongest prognostic factor.
  • In the present study, we aimed to evaluate which lymph node assessment method, metastatic lymph node number vs. ratio of metastasis, was better to predict survival in comparison with known prognostic factors in advanced gastric carcinoma in Korea.
  • Based on our study, we demonstrate that the MLR was a simple and reproducible prognostic factor that supplemented the limitation of the conventional N staging system, and provided more accurate prognostic stratification in advanced gastric cancer.
  • The MLR demonstrated further survival influence in pN2 stage.
  • Moreover, with the relationship to pT stage, MLR showed better survival information than that of ordinary AJCC pN stage.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428770.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


94. Wang SJ, Wu ML, Zhang LW, Guo XQ, Xu ZB, Er LM, Wang SP, Gao Y, Cong QW: [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia]. Zhonghua Zhong Liu Za Zhi; 2008 Nov;30(11):853-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia].
  • OBJECTIVE: To evaluate the long-term effect and clinical value of endoscopic mucosal resection (EMR) with transparent cap for dysplasia and early-stage cancer of the esophagus and gastric cardia.
  • METHODS: From September 1996 to June 2007, 154 lesions in the esophagus or gastric cardia of 147 patients were treated using EMR with transparent cap.
  • Among the lesions, there were 69 early-stage squamous-cell carcinomas in 64 patients and 47 squamous cell precancerous lesions of the esophagus in 45 patients, with an average lesion size of (14.8 +/- 6.1) mm (range, 3-40 mm), furthermore, there were 23 early-stage adenocarcinomas in 23 patients and 15 precancerous lesions in the gastric cardia in 15 patients, with an average lesion size of (8.2 +/- 4.3) mm (rang, 5-25 mm).
  • The 5-year survival rate was 96.2% for early-stage esophageal cancer, and 100% for early cancer of the gastric cardia.
  • CONCLUSION: Endoscopic mucosal resection is suitable to treat precancerous lesions or early-stage esophageal cancers without invasion into submucosa.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


95. Song KY, Jung CK, Park WS, Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol; 2009 May;39(5):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma.
  • OBJECTIVE: This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in Stage III gastric adenocarcinoma.
  • METHODS: We performed immunohistochemical staining for survivin, p53 and Bax in formalin-fixed, paraffin-embedded blocks from 157 surgically resected Stage III gastric cancer tissues.
  • RESULTS: Of the 157 gastric cancer tissues, 63 (40.1%) cases showed positive expression for survivin protein.
  • Survivin and p53 were independent prognostic factors in Stage III gastric cancer.
  • CONCLUSIONS: Survivin protein is an important predictive and prognostic parameter of poor outcome in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Microtubule-Associated Proteins / genetics. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336448.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


96. Dong Q, Liu YP, Qu XJ, Hou KZ, Li LL: [Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]. Chin J Cancer; 2010 Jan;29(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance].
  • This study investigated the expression of c-Cbl, Cbl-b, and EGFR in gastric carcinoma and its clinical significance.
  • METHODS: The expressions of c-Cbl, Cbl-b, and EGFR were detected by immunohistochemistry using tissue microarrays consisting of 124 specimens of gastric carcinoma and 16 specimens of normal gastric mucosa.
  • The relationship between the expressions of c-Cbl, Cbl-b, and EGFR and clinicopathologic factors of gastric carcinoma were analyzed statistically.
  • RESULTS: The positive rates of c-Cbl, Cbl-b, and EGFR were higher in the gastric carcinoma group than in the normal group (71.0% vs. 18.0%, P<0.01; 82.3% vs. 25.0%, P<0.01; 56.5% vs. 12.5%, P<0.01, respectively).
  • Synchronous strong-positive expressions of c-Cbl, Cbl-b, and EGFR were observed in 27 specimens of gastric carcinoma, most of which were at advanced stage.
  • CONCLUSIONS: Overexpressions of c-Cbl, Cbl-b, and EGFR are closely related to the invasion and progression of gastric carcinoma. c-Cbl and Cbl-b may serve as novel molecular markers for gastric carcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038312.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / CBLB protein, human
  •  go-up   go-down


97. Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY, Lee KH, Lee JH: CpG methylation of transcription factor 4 in gastric carcinoma. Ann Surg Oncol; 2010 Dec;17(12):3344-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG methylation of transcription factor 4 in gastric carcinoma.
  • BACKGROUND: Epigenetic silencing of tumor-related genes by CpG island methylation is an important mechanism for the development of many tumors, including gastric carcinoma.
  • Deregulation of transcription factor 4 (TCF4) by promoter methylation was recently shown to play a key role in gastric carcinogenesis.
  • METHODS: The extent of methylation in the TCF4 promoter was assessed using methylation-specific polymerase chain reaction (MSP) and pyrosequencing (PS) in 120 gastric carcinoma (GC) samples collected during gastrectomy, and in 40 normal gastric mucosa samples.
  • There was a significant difference in TCF4 methylation between GCs and normal gastric mucosa (67.5 vs. 40.0%, respectively, by MSP and 75.8 vs. 30.0%, respectively, by PS; p < 0.05).
  • There was significant correlation between TCF4 methylation status by PS and tumor size (p = 0.004), Lauren classification (p = 0.043), depth of invasion (p < 0.001), nodal metastasis (p = 0.021), and tumor-node-metastasis (TNM) stage (p = 0.045).
  • CONCLUSIONS: These results suggest that inactivation of TCF4 by promoter methylation may play a role in the early stage of gastric carcinoma progression.
  • [MeSH-major] Adenocarcinoma / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Signet Ring Cell / genetics. CpG Islands / genetics. DNA Methylation / genetics. Gastric Mucosa / pathology. Stomach Neoplasms / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585880.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / TCF4 protein, human; 0 / Transcription Factors
  •  go-up   go-down


98. Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I: Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol; 2006 Apr;8(4):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
  • OBJECTIVE: To calculate the Normal Tissue Complication Probabilities (NTCP) for the liver, right kidney, left kidney and spinal cord, as well as the global Uncomplicated Tumour Control Probability (UTCP) in gastric cancer patients who underwent a treatment with radiotherapy after radical surgery in our environment.
  • MATERIAL AND METHOD: In April 2000, a postoperative chemotherapy (QT-RT) protocol started in the province of Malaga for Gastric Adenocarcinomas with postsurgical stage II or higher (pT3-4 and/or pN+).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Kidney / radiation effects. Liver / radiation effects. Radiation Injuries / diagnosis. Radiotherapy, Adjuvant / adverse effects. Spinal Cord / radiation effects. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [2032884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):283-93 [11872272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30 [2722599.001]
  • [Cites] Radiat Res Suppl. 1985;8:S13-9 [3867079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):439-47 [10760441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):589-98 [10701738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):983-93 [10705021.001]
  • (PMID = 16648103.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. Michelet P, D'Journo XB, Roch A, Papazian L, Ragni J, Thomas P, Auffray JP: Perioperative risk factors for anastomotic leakage after esophagectomy: influence of thoracic epidural analgesia. Chest; 2005 Nov;128(5):3461-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most important predisposing factors for anastomotic leaks are ischemia of the gastric conduit and low blood oxygen content.
  • PATIENTS: Two hundred seven patients who underwent one-stage esophagectomy between 1998 and 2003.
  • [MeSH-major] Adenocarcinoma / surgery. Analgesia, Epidural. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304300.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


100. Yu QS, Liu Y, Hou Y, Zhang F, Yi W, Wang X, Shuai J: [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Aug;25(8):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation].
  • OBJECTIVE: To explore the regulation and clinical significance of intestinal dripping of Jianpi Tongli (JPTL) Chinese herbs on levels of serum cytokines, such as interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and interleukin-12 (IL-12) in treating patients with gastric cancer (GC) at early post-operational stage.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16152828.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down






Advertisement